

## Supplementary Information

### Supplementary Text

#### *Data Requirements and Reproducibility*

In order to test the data requirements of the modulatory profiles, we calculated the potency and efficacy shifts using only half of the data points (7-point, 4-fold dilution series). The correlation between these parameters and those calculated with the full data set (Spearman correlation = 0.809) was deemed too low to allow for the use of fewer data points in such experiments (see Fig. S3a), since these sets of parameters were calculated from the same biological data.

To determine the reproducibility of the parameters, 5 compounds were repeated in separate batches (camptothecin, daunorubicin, vinblastine, MG132, and erastin). The comparison between the changes in potency and efficacy between batches are shown in Figure S3b. Consistency between batches was high (Spearman correlation for potency 0.799, for efficacy 0.709) and replicates clustered together within the larger dataset (see Fig. 2b and 4c). The parameters calculated from the same modulator used in different cell lines were related but different (Fig. S3c, Spearman correlation 0.417). If the correlation were perfect, it would not be useful to include both cell lines. Thus, this positive correlation demonstrated that while the two cell lines provide non-redundant information, we are identifying aspects of cell death pathways that are consistent across cell lines. We also repeated a subset of compounds using both Alamar blue and CellTiterGlo as the viability detection reagent (Fig. S3d). The correlation between the parameters calculated was high (Spearman correlation for potency 0.710, for efficacy 0.847), similar to the difference between replicates of the same compound using Alamar blue. This allowed for the use of exclusively Alamar blue in the bulk of the experiments. The modulators had very little effect on the Alamar blue signal in the absence of cells (Fig. S3e), although some modulators did affect cell viability (Fig. S3f). These effects were subtracted and normalized, respectively, and therefore have no impact on the calculated changes in potency and efficacy.

#### *Clustering of Compounds Based on Individual Modulators*

Concentration-response curves for 6 lethal compounds in the presence and absence of 4 different modulators are depicted in Fig. S2. The use any one of these four modulators is generally poor at clustering compounds together that have the same known mechanism of action. This is demonstrated in the dendograms shown in Fig. S4. While individual modulators can differentiate specific compound classes (most notably deferoxamine and microtubule destabilizers in Fig. S4), a broad modulatory profile is required to accurately cluster all of the compound classes.

#### *Clustering of Compounds Based on Chemical Structure*


There is a great deal of interest in using informatics tools to predict small molecule bioactivities and targets(1, 2). We clustered the compounds in our set of characterized compounds based on a modified Tanimoto coefficient(3) to determine if the clusters of compounds with the same biological activity that we identified using modulatory profiling could have been predicted based purely on the compounds' structures. The resulting dendrogram (Fig. S7) shows that apart from a small number of

similarly acting analogs (e.g. vincristine and vinblastine), mechanistic classes are not broadly related structurally. In conclusion, modulatory profiles demonstrate biological activity relationships between compounds that would not be predicted based on their structures.

#### *Compound Reactivity Required for Lethality of Some Lethal Compounds*


We examined one member of cluster B further to test the importance of reactivity on lethality. NPC17 is a 14-hydroxy analog of codeinone, an opiate containing an  $\alpha,\beta$ -unsaturated carbonyl group. Opiates, widely used as analgesics, have been tested previously for lethality in cell culture. Most studies have found codeinone, the only analog tested with an electrophilic  $\alpha,\beta$ -unsaturated carbonyl group, to be the only substantially cytotoxic opiate derivative(4). We tested the opiates morphine, codeine, codeinone, oxycodone, and hydrocodone for toxicity in HT-1080 and BJ-TERT/LT/ST/RAS<sup>V12</sup> cells. Consistent with previous reports, NPC17 and codeinone both killed cells at concentrations of approximately 1  $\mu$ M, while none of the other analogs killed cells at the highest concentration tested (300  $\mu$ M, see Fig. S10a and b). These data support the hypothesis that members of cluster B are lethal largely due to their chemical reactivity.

#### Supplementary Figures




#### **Supplementary Figure 1: Validation of Genetic Modulators**

- (a) Protein expression of Bcl-2 (left) and Survivin (right) after infection with the indicated cDNA. Infection with a LacZ expressing cDNA was used as a control.
- (b) Protein expression of Beclin (left) and p53 (right) after infection with the indicated shRNA clones. A non-targeting shRNA (NT) was used as a control. Quantification of knockdown relative to the non-targeting is shown below each blot.



### Supplementary Figure 2: Additional Examples of Concentration-Response Curves

Concentration-response curves for the topoisomerase I inhibitor camptothecin, the microtubule destabilizers podophyllotoxin and colchicine, the proteasome inhibitor MG132, and the HDAC inhibitors MS275 and scriptaid in HT-1080 cells in the presence and absence of the indicated concentrations of (a) deferoxamine, (b) ALLN, (c) CoCl<sub>2</sub>, and (d) digoxin.



**Supplementary Figure 3: Data Requirements, Reproducibility, and Detection Reagent Dependence**

(a) Dot plot showing the difference in the modulatory profile parameters calculated using the entire 14 dose-point data set compared to the parameters calculated using 7 dose

points. Potency and efficacy changes were normalized so that both had a standard deviation of one (for all compounds, not for each compound).


(b) Inter-batch comparison of potency and efficacy parameters for compounds that were replicated in separate batches. The Spearman correlation between the parameters was 0.799 for potency and 0.709 for efficacy.

(c) Comparison of the parameter values (potency, efficacy) calculated for the same modulator in the two different cell lines. The Spearman correlation between the cell lines is 0.417.

(d) Comparison of parameters determined using Alamar blue as the detection reagent and those calculated using CellTiterGlo for 5 lethal compounds in the presence and absence of CoCl<sub>2</sub>, cycloheximide, or ZVAD in BJ-TERT/LT/ST/RAS<sup>V12</sup> cells or SP600125, NAD+, or TOC in HT-1080 cells. The Spearman correlation between the parameters was 0.710 for potency and 0.847 for efficacy.


(e) Effect of the modulators on Alamar blue signal in the absence of cells. The indicated modulators were incubated in the media used for the indicated cell lines for 48 hours before the addition of Alamar blue. Fluorescence counts obtained from a well without the modulator was subtracted from the counts with the modulator. This difference was then divided by the counts from a well of cells without modulator in order to produce a percent increase in signal caused by the modulator. Values represent the mean of 12 replicates  $\pm$ SEM.

(f) Effect of the modulators on cell viability. The indicated cell lines were grown in the presence of the indicated modulators. Values were normalized to cells grown in the absence of the modulators. Values represent the mean of 6 replicates  $\pm$ SEM.




**Supplementary Figure 4: Dendrograms from Clustering Based on a Single Modulator**

Dendrograms derived from clustering the lethal compounds based only on the indicated modulators used in HT-1080 cells.




**Supplementary Figure 5: Tubulin Immunofluorescence in HT-1080 Cells**

Anti-tubulin immunofluorescence images in HT-1080 cells after 90-minute treatment with DMSO vehicle, 5  $\mu$ M rotenone, 0.25  $\mu$ M colchicine, or 1  $\mu$ M staurosporine.




**Supplementary Figure 6: Acetylated Tubulin Immunofluorescence with Mitochondrial Inhibitors**

TC-7 cells stained for acetylated tubulin after a 1 or 6 hour treatment with vehicle (DMSO), 20 nM vinblastine, 200 nM valinomycin, 10  $\mu$ M antimycin A, or 1mM disodium malonate. Representative images were chosen for each treatment. The scale bar in the upper left panel is 10  $\mu$ m and is the same in each panel.




**Supplementary Figure 7: Structure-based Clustering of Lethal Compounds**

Dendrogram produced from hierarchical clustering of compounds based on structure. A modified Tanimoto coefficient was used as a similarity metric.




**Supplementary Figure 8: Heat Map of Modulatory Profiles for Characterized and Uncharacterized Compounds**

Heat map depicting the modulatory profile of 45 compounds (and 5 repeated compounds). Both axes are clustered using the Spearman correlation as the metric. Colored bars on the left side of the heat map correspond to the clusters highlighted in Fig. 4c. From top to bottom, these are cluster A (light green, uncharacterized), cluster B (red, reactive compounds), cluster C (blue, hydrophobic amines), cluster D (gray, characterized targeted mechanisms), and cluster E (green, uncharacterized Bax/Bak independent mitochondrial death). The microtubule destabilizers within cluster D are highlighted in black.




**Supplementary Figure 9: Acetylated Tubulin Immunofluorescence with Compounds from Clusters B, C, and E**

TC-7 cells stained for acetylated tubulin after a 1 or 6 hour treatment with vehicle (DMSO), 20 nM vinblastine, 1mM carmustine, 30  $\mu$ M NPC23, 10  $\mu$ M NPC26, or 20  $\mu$ M erastin. The scale bar in the upper left panel is 10  $\mu$ m and is the same in each panel.



### Supplementary Figure 10: Novel Compounds Act Nonspecifically

- (a) Structures of NPC17 and the other opiates tested.
- (b) EC<sub>50</sub> values in μM of the compounds shown in (a). Compounds that were not lethal are shown with an EC<sub>50</sub> equal to the highest concentration tested (300 μM).
- (c) Phase contrast microscopy images of HT-1080 cells treated for 40 minutes with the indicated compounds.



**Supplementary Figure 11: Novel Compounds Induce Bax/Bak-Independent Mitochondrial Cell Death**

- (a) Heat map depicting the potency and efficacy changes obtained for NPC26 with the indicated modulators (x-axis) in the indicated cell lines (y-axis).
- (b) Concentration-response curves of erastin, RSL3, NPC26, Staurosporine, and Scriptaid in HT-1080 and BJ-TERT/LT/ST/RAS<sup>V12</sup> cells co-treated with vehicle or 45 μM ZVAD.

- (c) Fluorescence images of HT-1080 cells expressing a mitochondrially targeted dsRed construct, treated with the indicated compounds for the indicated amounts of time.
- (d) Protein expression of DRP1 after infection with lentivirus encoding one of five different shRNAs targeting DRP1 or a control non-targeting shRNA (NT). DRP1/Actin ratio relative to the non-targeting construct is quantitated below. The mean of two replicates  $\pm$ SEM is graphed.
- (e) Mitochondrial membrane potential as measured by aggregated JC-1 fluorescence. Cells were treated with compounds for one hour prior to analysis by FACS.
- (f) Concentration-response curves for NPC26 and two NPC26 analogs (26A3 and 26A14) in BJ-TERT/LT/ST/RAS<sup>V12</sup> cells in the presence and absence of the kinase inhibitor SP600125.

## Supplementary Methods

### *Cell lines, reagents, and clones*

BJ-TERT/LT/ST/RAS<sup>V12</sup>, HT-1080, Calu-1, and U-2-OS cells were cultured as described previously(5, 6). The wild-type and *Bax*<sup>-/-</sup>*Bak*<sup>-/-</sup> mouse embryonic fibroblasts were kindly provided by Dr. Craig Thompson and were cultured in DMEM supplemented with 10% calf serum. For sources of chemicals, please see Supplementary Tables 1 and 2.

Clones for shRNAs were purchased from Sigma-Aldrich and the most effective clone by western blot chosen for use in modulatory profiling (p53 - TRCN0000010814, Beclin - TRCN0000033549, see supplementary figure 1B; Drp1 - TRCN0000001099, see Supplementary Fig. 5c). Lentivirus was prepared as described previously(7, 8). cDNAs were purchased from the Harvard Institute of Proteomics (Bcl2 clone ID - HsCD00040340, Survivin clone ID - HsCD00004976) and moved into pLenti6/V5-DEST Gateway™ Vector (Invitrogen V496-10) using the Invitrogen LR recombination system (11824-026). Virus was then prepared and utilized in the same manner as with the shRNA clones.

### *Cell survival assays*

Cells were trypsinized, counted, and combined with modulators or with vehicle and seeded into 384-well plates (600/well for BJ-TERT/LT/ST/RAS<sup>V12</sup>, 1000/well for HT-1080 cells). Cell-death-inducing agents were dissolved in DMSO and arrayed in 14-point dilution series in 384-well polypropylene plates (Greiner, cat. #781280) and stored at -80°C. These plates were diluted 1:25 into cell culture media in polypropylene plates, then 1:10 into the assay plates approximately one hour after cells were seeded. After 48 hours, a 50% Alamar blue solution was added to a final concentration of 10% Alamar blue. After 16 hours of incubation, the fluorescence intensity was determined using a Victor 3 plate reader (Perkin Elmer) with a 535 nm excitation filter and a 590 nm emission filter. All assays were done in at least triplicate.

### *Determination of changes in potency and efficacy*

Background was subtracted from raw fluorescence measurements (media only, modulator only, and lethal compound only background). Values were normalized to vehicle or modulator-only controls and values above 1 and below 0 were soft-thresholded by reducing the amount above the cutoff by 80%. Four parameter logistic best-fit concentration-response curves (parameters are Top, Bottom, logEC50, and HillSlope) were constructed for each of the replicates using GraphPad Prism™ software with constraints of Top=1 and Bottom>0. Outliers were removed using Prism's built-in ROUT algorithm(9). The change in potency was defined as the log ratio of the concentration of compound in the presence of modulator to the concentration in the absence of modulator required to produce a level of cell survival equal to the half maximal reduction in viability produced in the absence of the modulator. Efficacy changes were defined as the difference between the curves in the presence versus the absence of modulator at the highest concentration of lethal compound tested.

The efficacy measurement was deemed unreliable when no measurement was taken at a concentration close to the bottom of the curve and a missing value was assigned in its place. This occurred primarily due to (i) large shifts in potency that

shifted the bottom of the curve outside of the concentration range tested and (ii) solubility limits of compounds that prevented reliable determination of the bottom of the curve. Missing values were inserted for efficacy when the difference between the control and modulator curves at the highest concentration tested (dEff) differed greatly from the difference in the Bottom parameter fit for the curves (dBot). The following criteria were applied:

- Only accept opposite signs if very close
  - if  $dEff * dBot < 0$ ,  $\max(\text{abs}(dEff, dBot)) > 0.5\%$  → missing value
- Throw out values with large difference (unless both large)
  - if  $\text{abs}(dEff - dBot) > 5\%$ ,  $\min(dEff, dPot) < 5\%$  → missing value
- Throw out values if ratio is large (unless both very small)
  - if  $dEff/dBot > 10$  or  $< 0.1$ ,  $\max(dEff, dPot) > 0.5\%$  → missing value
  - if  $dEff/dBot > 5$  or  $< 0.2$ ,  $\max(dEff, dPot) > 2\%$  → missing value

Topoisomerase inhibitors can produce biphasic concentration-response curves due to inhibition of the religation function of topoisomerases at low concentrations (leading to large scale DNA damage) but inhibition of topo-DNA complex formation at higher concentrations (preventing the DNA damage)(10-12). We were unable to fit these biphasic curves with our standard four-parameter logistic fit. For curves with these features, we calculated potency shifts based solely on the first phase of the curve and inserted missing values for the change in efficacy.

To remove the decreasing trend in the potency that occurred in the chronological course of each experiment, one assay plate without modulator was treated with each set of triplicates of the modulators. The potency of all the modulator-free plates were plotted and fit with a linear regression. This linear regression was used to calculate the potency value for each modulator based on the position that modulator triplicate set had with respect to the modulator-free plates.

#### *Comparing and clustering modulatory profiles*

Potency and efficacy changes were normalized so that both had a standard deviation of one (for all compounds, not for each compound). Spearman correlation coefficients were calculated between each pair of lethal compounds to give a similarity matrix. The similarity matrix was clustered using the R functions agnes or hclust with the group average method for defining new clusters(13).

#### *Preprocessing and clustering based on gene expression profiles*

Microarray data were downloaded from the Broad's Connectivity Map website (<http://www.broadinstitute.org/cmap/>) as CEL files. For the experiments included in our analysis, cells were treated with compound for 6 hours before lysis and mRNA collection. More detailed description of the experimental protocols are available on the website and in the publication about the project(14). We performed probeset summarization using the MAS5 algorithm(15). Values were converted to a log2 scale and those under 5 were thresholded to 5. Probesets that were very low (average  $< 5.02$ ) or invariant (standard deviation  $< 0.15$ ) across the entire 281-array dataset were removed. When multiple probesets were present for the same gene, these probesets were compared

to each other to determine their reliability. If all probesets correlated with each other above the threshold (Pearson correlation 0.5), all were kept. If not, a series of procedures were applied to eliminate the less reliable probeset(s). These included (i) excluding single data points that significantly reduced the correlation between probesets, (ii) excluding consistently low probesets (probeset average is more than 2 standard deviations less than the average of all probesets), (iii) identifying a subset of the probesets that were well-correlated with each other and discarding the others. If none of these procedures were successful in identifying the most reliable probesets, all probesets for that gene were removed from the dataset. Each treatment array was normalized to the average of the batch-matched vehicle-only controls and all remaining redundant probesets for the same gene were averaged together.

Spearman correlations were calculated between each pair of compounds based on their expression profiles across MCF7 and PC3 cells (PC3 data was available for a subset of the compounds; when not available, the correlation was calculated based only on the MCF7 data). Multiple concentrations of the same compound were treated as independent instances. Clustering was performed as described for modulatory profiles.

#### *Immunofluorescence*

Cells were grown on coverslips and then treated with the appropriate compounds for the indicated length of time. Cells were fixed in methanol (-20°C) and slips were blocked in 10% horse serum. Cells were stained with mouse monoclonal anti-acetylated tubulin antibody clone 6-11-B1 (Sigma T7451, 1:200) and rabbit polyclonal anti-tubulin antibody (anti-tyrosinated and anti-detyrosinated(16), 1:200) and an appropriate alexa-conjugated secondary, mounted on slides with Fluoromount-G (Southern Biotech, 0100-01) containing DAPI (Sigma), and imaged with the 60x lens of an epifluorescence microscope. Microtubules can be acetylated post-translationally, a modification found only on tubulin polymers and not on monomers(16). Staining for acetylated tubulin allowed us to visualize only the remaining polymerized tubulin as the microtubules were broken down.

#### *Caspase Activity*

Caspase activity was measured using the Apo-ONE Homogenous Caspase-3/7 Assay (Promega G7791). HT-1080 cells were seeded in 384-well plates and treated with lethal compounds as described above for cell survival assays. After 12-15 hours, 10 µL of substrate solution/lysis buffer mix were added to each well. Plates were shaken and then incubated at room temperature for 15 hours. Fluorescence intensity was measured using a Victor 3 plate reader (Perkin Elmer) with a 490 nm excitation filter and a 535 nm emission filter. A cell survival assay was performed using Alamar blue on plates treated in parallel but after 48 hours of lethal compound treatment.

#### *Chemical Informatics and statistics*

Compounds were clustered based on structure using the software ChemmineR(17). Structures in structure definition file (SDF) format were imported into ChemmineR and converted into atom pair descriptors. Similarities between each pairwise combination of structures were calculated using a modified Tanimoto coefficient which is robust to changes in molecular size(3) and assembled into a similarity matrix.

This similarity matrix was clustered as described for modulatory profiles and gene expression profiles within the R environment.

Reactivity filtering and analysis of fraction nonpolar van der Waals surface area were performed with the MOE software. Most basic pKa was determined using the web-based software SPARC(18). For one compound, 2,4 dinitrophenol, no pKa could be calculated for the most basic residue. This compound was therefore omitted from the graph in figure 6b but included in the table since its polarity alone defined it as outside of the shaded quadrant.

Statistical comparison between groups was performed using a one-way ANOVA and Tukey's multiple comparison test.

#### *Fluorescent imaging of mitochondria*

Cells were transfected with pDsRed2-mito (Clontech 632421) using FuGENE 6 transfection reagent and selected with G418 (500 ug/ml) for at least one week in culture. Cells were plated on coverslips and treated with compounds for the indicated length of time. After fixation with 3.7% paraformaldehyde in PBS, coverslips were mounted on slides with Fluoromount mounting media with 10  $\mu$ g/ml Hoescht 33342 (Molecular Probes H3570) and visualized with the 100x lens of an inverted epifluorescence microscope.

#### *Western Blots*

After aspiration of the medium, cells were washed twice with ice cold PBS. Cells were then treated on ice for 10 minutes with lysis buffer (50mM HEPES, 40mM NaCl, 2mM EDTA, 0.5% Triton-X, 1.5mM sodium orthovanadate, 50mM NaF, 10mM sodium pyrophosphate, 10mM sodium  $\beta$ -glycerophosphate, and protease inhibitor tablet (Roche 11836170001), pH 7.4). Samples were separated using SDS-polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane, blocked for 1 hour at room temperature in Licor Odyssey Blocking Buffer (927-40000) and then incubated with the appropriate primary and secondary antibodies: anti-Bcl-2 (Santa Cruz sc-7382), anti-survivin (Novus Biologicals NB500-201), anti-p53 (Calbiochem OP43), anti-Beclin (BD Transduction Laboratories 612112), anti-actin (Santa Cruz sc-1616), anti-tubulin (Santa Cruz sc-32293), anti-DLP1 (DRP1) (BD Transduction Laboratories 611112). Membranes were scanned using the Licor Odyssey Imaging System.

#### *Electron Microscopy*

Cells were incubated for 3 or 6 hours in the presence of DMSO or 9 $\mu$ M NPC26, fixed with 2.5% glutaraldehyde in 0.1M Sorenson's buffer (0.1 M H<sub>2</sub>PO<sub>4</sub>, 0.1 M HPO<sub>4</sub> (pH 7.2)) for at least 1 h, and then treated with 1% OsO<sub>4</sub> in 0.1 M Sorenson's buffer for 1 h. Enblock staining used 1% tannic acid. After dehydration through an ethanol series, cells were embedded in Lx-112 (Ladd Research Industries) and Embed-812 (EMS). Thin sections were cut on an MT-7000 ultramicrotome, stained with 1% uranyl acetate and 0.4% lead citrate, and examined under a Jeol JEM-1200 EXII electron microscope. Pictures were taken on an ORCA-HR digital camera (Hamamatsu) at the indicated magnification, and measurements were made using the AMT Image Capture Engine.

#### *Measurement of change in mitochondrial membrane potential ( $\Delta\Psi_{mito}$ )*

Procedure was performed using the MitoProbe<sup>TM</sup> JC-1 Assay Kit (M34152) following the manufacturers protocol. Briefly, HT-1080 cells were trypsinized and resuspended in 1 ml of media with 2  $\mu$ M JC-1 and with or without appropriate compound treatment. After incubation for 20 minutes at 37°C, cells were spun down and resuspended in PBS without JC-1 but containing appropriate compound treatment. Cells were strained through a 40  $\mu$ m cell strainer to remove clumps and analyzed by flow cytometry (FACSCalibur; Becton Dickinson).

### *Chemical Identity*

For commercial compounds explored in depth (NPC4, 7, 25), molecular formulas were confirmed by high-resolution mass spectroscopy.


### *Synthesis and Characterization of NPC26 analogs*

#### **General Information:**

Chemicals: Solvents, inorganic salts, and organic reagents were purchased from commercial sources and used without further purification unless otherwise mentioned.


Chromatography: Merck pre-coated 0.25 mm silica plates containing a 254 nm fluorescence indicator were used for analytical thin-layer chromatography. Flash chromatography was performed on 230-400 mesh silica (SiliaFlash® P60) from Silicycle. Spectroscopy: NMR spectra were obtained on a Bruker DPX 300 or 400 MHz spectrometer. CI-MS spectra were taken on a Nermag R-10-10 instrument.

#### **Synthesis of various NPC26 analogs**




### **Preparation of NPC26 and analogs: general protocol**

To the ethyl 2-amino-5,5,7,7-tetramethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate (**1**), which was prepared following known procedure(19), in dry dichloromethane (DCM) was added diisopropylethylamine (DIPEA) (1.1 equiv) under nitrogen. At 0°C various acyl chlorides (1.1 equiv) were added and the mixtures were stirred for 17 h at room temperature. Aqueous bicarbonate was added and the organic phases were separated. The aqueous phases were extracted three times with Dichloromethane (DCM). After drying with anhydrous magnesium sulfate the solvents were removed under vacuum. The crudes were purified by silica gel.




**Ethyl 5,5,7,7-tetramethyl-2-(2-nitrothiophene-5-carboxamido)-4,5,6,7-tetrahydrothieno [2,3-c]pyridine-3-carboxylate (NPC26).**

Following the above general procedure with the amine (**1**) (550 mg, 1.947 mmol), DIPEA (332  $\mu$ L, 4.284 mmol) and 5-nitrothiophene-2-carbonyl chloride (555 mg, 2.920 mmol), the crude reaction mixture was purified by column chromatography (DCM/MeOH) to provide the solid **NPC26** (610 mg, 1.396 mmol, 72%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400MHz, ppm)  $\delta$  12.49 (b, NH), 7.90 (d,  $J$  = 4 Hz, 1H), 7.61 (d,  $J$  = 4 Hz, 1H), 4.42 (q,  $J$  = 7.2 Hz, 2H), 2.69 (s, 2H), 1.50 (s, 6H), 1.43 (t,  $J$  = 7.2 Hz, 3H), 1.22 (s, 6H); MS (APCI+,  $M+I$ ) 437.71.




**Ethyl 5,5,7,7-tetramethyl-2-(3-(trifluoromethyl)benzamido)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylate (SRS1-04).**

Following the above general procedure with the amine (**1**) (100 mg, 0.354 mmol), DIPEA (67  $\mu$ L, 0.389 mmol) and 3-(trifluoromethyl)benzoyl chloride (57.6  $\mu$ L, 0.389 mmol), the crude reaction mixture was purified by column chromatography (DCM/MeOH) to provide the solid **SRS1-04** (95 mg, 0.209 mmol, 60%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400MHz, ppm)  $\delta$  12.44 (b, NH), 8.30 (s, 1H), 8.15 (d,  $J$  = 8.0 Hz, 1H), 7.86 (d,  $J$  = 8.0 Hz, 1H), 7.68 (t,  $J$  = 8.0 Hz, 1H), 4.41 (q,  $J$  = 6.8 Hz, 2H), 2.74 (s, 2H), 1.55 (s, 6H), 1.43 (t,  $J$  = 6.8 Hz, 3H), 1.25 (s, 6H); MS (APCI+,  $M+I$ ) 455.66.




**Ethyl 5,5,7,7-tetramethyl-2-(perfluorobenzamido)-4,5,6,7-tetrahydrothieno[2,3c]pyridine-3-carboxylate (SRS1-05).**

Following the above general procedure with the amine (**1**) (100 mg, 0.354 mmol), DIPEA (67  $\mu$ L, 0.389 mmol) and 2,3,4,5,6-pentafluorobenzoyl chloride (53.90  $\mu$ L, 0.389 mmol), the crude reaction mixture was purified by column chromatography (DCM/MeOH) to provide the solid **SRS1-05** (75 mg, 0.157 mmol, 45%).  $^1$ H NMR ( $\text{CDCl}_3$ , 400MHz, ppm)  $\delta$  12.10 (b, NH), 4.37 (q,  $J$  = 7.2 Hz, 2H), 3.05 (s, 2H), 1.89 (s, 6H), 1.60 (s, 6H), 1.38 (t,  $J$  = 7.2 Hz, 3H); MS (APCI+, M+1) 477.07.




**Ethyl 5,5,7,7-tetramethyl-2-(4-(trifluoromethyl)benzamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate (SRS1-06).**

Following the above general procedure with the amine (**1**) (100 mg, 0.354 mmol), DIPEA (67  $\mu$ L, 0.389 mmol) and 4-(trifluoromethyl)benzoyl chloride (57.9  $\mu$ L, 0.389 mmol), the crude reaction mixture was purified by column chromatography (DCM/MeOH) to provide the solid **SRS1-06** (107 mg, 0.235 mmol, 66%).  $^1$ H NMR ( $\text{CDCl}_3$ , 400MHz, ppm)  $\delta$  12.49 (b, NH), 8.13 (d,  $J$  = 8.0 Hz, 1H), 7.80 (d,  $J$  = 8.0 Hz, 1H), 8.15 (d,  $J$  = 8.0 Hz, 1H), 7.86 (d,  $J$  = 8.0 Hz, 2H), 7.68 (t,  $J$  = 8.0 Hz, 2H), 4.41 (q,  $J$  = 7.2 Hz, 2H), 2.74 (s, 2H), 1.55 (s, 6H), 1.43 (t,  $J$  = 7.2 Hz, 3H), 1.25 (s, 6H); MS (APCI+, M+1) 455.00.





**Ethyl 5,5,7,7-tetramethyl-2-(5-(2-(trifluoromethyl)phenyl)furan-2-carboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate (SRS1-39).**

Following the above general procedure with the amine (**1**) (100 mg, 0.354 mmol), DIPEA (67  $\mu$ L, 0.389 mmol) and 5-(2-(trifluoromethyl)phenyl)furan-2-carbonyl chloride (106.8 mg, 0.389 mmol), the crude reaction mixture was purified by column chromatography (DCM/MeOH) to provide the solid **SRS1-39** (120 mg, 0.23 mmol, 65%).  $^1$ H NMR ( $\text{CDCl}_3$ , 400MHz, ppm)  $\delta$  12.11 (b, NH), 7.85-7.79 (m, 2H), 7.65 (t,  $J$  = 7.6 Hz, 1H), 7.54 (t,  $J$  = 7.6 Hz, 1H), 7.37 (d,  $J$  = 4.0 Hz, 1H), 6.83 (d,  $J$  = 4.0 Hz, 1H), 4.35 (q,  $J$  = 7.2 Hz, 2H), 2.71 (s, 2H), 1.51 (s, 6H), 1.35 (t,  $J$  = 7.2 Hz, 3H), 1.22 (s, 6H); MS (APCI+, M+1) 506.98.




To the **NPC26** compound (10 mg, 0.0228 mmol) in dry DCM (0.5 mL) was added NaHCO<sub>3</sub> (9.6 mg, 0.1143 mmol). At 0°C mCPBA (4.3 mg, 0.0251 mmol) was added and the mixtures were stirred for 1h at room temperature. Sodium bicarbonate solution was added and the organic phase was separated and the aqueous phase was extracted three times with 1 mL of DCM. After drying with anhydrous magnesium sulfate the solvents were removed under vacuum. The crude was purified by Preparative TLC plate (hexane / ethylacetate) to provide the solid **Ox\_NPC26** (4 mg, 0.009 mmol, 40%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400MHz, ppm) δ <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400MHz, ppm) δ 12.36 (b, NH), 7.94 (d, *J*= 4 Hz, 1H), 7.68 (d, *J*= 4 Hz, 1H), 4.57 (m, 2H), 2.69 (s, 2H), 1.50 (s, 6H), 1.43 (m, 3H), 1.22 (s, 6H); MS (APCI+, *M*+1) 454.00.

### Synthesis of SRS1-078 analog




**2-(2-(tert-butoxycarbonyl)ethoxy)ethyl 2-cyanoacetate (4).** To the 2-(2-aminoethoxy)-ethanol in ethanol (10 mL) was added di-*tert*-butyl dicarbonate. The mixture was stirred at room temperature for 17h. The solvent was removed and the NBOC compound was verified by NMR and mass spectroscopy and used without further purification.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400MHz, ppm)  $\delta$  5.01 (b, NH, 1H), 4.35 (s, 2H), 3.73 (s, 2H), 3.55 (m, 4H), 3.32 (m, 2H), 2.48 (b, OH, 1H), 1.43 (s, 9H); MS (APCI+, M+1) 206.00.

To the NBOC compound (1 equiv) in dichloromethane (DCM) (20 mL), 2-cyanoacetic acid (**3**) (1 equiv), 4-dimethylaminopyridine (DMAP) (0.2 equiv) were added. At 0°C *N,N'*-dicyclohexylcarbodiimide (DCC) (1 equiv) was added and the mixture was stirred for 17h at room temperature. The dicyclohexylurea (DCU) was filtered and the solvent was removed. The residue was purified by column chromatography (hexane/ethylacetate) to provide the oil (**4**) (120 mg, 0.23 mmol, 65%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400MHz, ppm)  $\delta$  4.92 (b, NH 1H), 4.35 (s, 2H), 3.69 (s, 2H), 3.53 (m, 4H), 3.31 (m, 2H), 1.43 (s, 9H); MS (APCI+, M+1) 273.00.



**2-(2-(tert-butoxycarbonyl)ethoxy)ethyl 2-amino-5,5,7,7-tetramethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate (6).**

Diethylamine (100  $\mu\text{L}$ , 0.966 mmol) was added to a stirred mixture of 2,2,6,6-tetramethyltetrahydro-4-pyridinone (**5**) (142.5 mg, 0.918 mmol), 2-(2-(tert-butoxycarbonyl)ethoxy)ethyl 2-cyanoacetate (**4**) (250 mg, 0.918 mmol), elemental sulfur (44.2 mg, 1.377 mmol), and DMF (1.5 mL). Stirring was continued for 17 hours at 50 °C. After mixing with  $\text{H}_2\text{O}$  (15 mL), the dark reaction mixture was extracted three times with 5 mL of EtOAc. After drying with anhydrous magnesium sulfate the solvent was removed under vacuum. The residue was purified by column chromatography (DCM/MeOH) to provide the solid (**6**) (250 mg, 0.566 mmol, 62%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400MHz, ppm)  $\delta$  6.00 (b, NH<sub>2</sub> 2H), 5.29 (b, NH 1H), 4.91 (m, 2H), 3.72(m, 2H), 3.55(m, 2H), 3.32 (m, 2H), 2.75 (s, 2H), 1.52 (s, 6H), 1.44 (s, 6H), 1.33 (s, 6H); MS (APCI+, M+1) 442.20.



**2-(2-(tert-butoxycarbonyl)ethoxy) ethyl 5,5,7,7-tetramethyl-2-(2-nitrothiophene-5-carboxamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate (SRS1-078)**

To the compound (**6**) (151 mg, 0.342 mmol) in 3 mL of dry dichloromethane (DCM), under nitrogen, was added diisopropylethylamine (DIPEA) (80  $\mu$ L, 1.026 mmol). At 0°C the 5-nitrothiophene-2-carbonyl chloride (130 mg, 0.684 mmol) was added and the mixture was stirred for 17h at room temperature. Aqueous bicarbonate was added and the organic phases were separated and the aqueous phases were extracted three times with EtOAc. After drying with anhydrous magnesium sulfate the solvent was removed under vacuum and the crude reaction mixture was purified by column chromatography (DCM/MeOH) to provide the solid **SRS1-078** (145 mg, 0.243 mmol, 71%).  $^1$ H NMR ( $\text{CDCl}_3$ , 400MHz, ppm)  $\delta$  12.31 (b, NH), 7.93 (d,  $J$  = 4 Hz, 1H), 7.64 (d,  $J$  = 4 Hz, 1H), 4.85 (b, NH), 4.49 (m, 2H), 3.80 (m, 2H), 3.59 (m, 2H), 3.34 (m, 2H), 2.71 (s, 2H), 1.50 (s, 6H), 1.43 (s, 9H), 1.22 (s, 6H); MS (APCI+, M+1) 597.35.

## Supplementary Tables

**Supplementary Table 1: Chemical and Genetic Modulators of Cell Death**

Details of the names, abbreviations, concentrations, suppliers, and mechanisms of action (and literature support for that mechanism) of the chemical and genetic modulators of cell death that were used.

Chemical or Genetic Modulator	Abbrev	Mechanism	Conc ( $\mu$ M)	Supplier (Cat#)	Reference(s)
Cbz-val-ala-asp(OMe)-fluoromethylketone	ZVAD	Broad spectrum caspase inhibitor	45	Biomol (P416-0001)	(20, 21)
t-butoxycarbonyl-aspart fluoromethylketone	BOCD	Broad spectrum caspase inhibitor	50	MPBio (03FK011)	(21, 22)
Calpain Inhibitor I	ALLN	Inhibitor of calpain I and II, cathepsins B,L	6.3	Calbiochem (208719)	(23)
N <sup>3</sup> -tosyl-lys-chloromethylketone	TLCK	Inhibitor of trypsin-like serine proteases	135	Roche (10874485001)	(24, 25)
Pepstatin	Pep	Inhibitor of cathepsin D	1.0	Roche (11359053001)	(26)
Cobalt (II)	Co <sup>2+</sup>	Blocks calcium channels	656	Sigma (C8661)	(27)
Gadolinium (III)	Gd <sup>3+</sup>	Blocks calcium channels	20	Aldrich (G7532)	(28)
3-methyladenine	3MA	Inhibitor of autophagosome formation	5000	Sigma (M9281)	(29, 30)
Nicotinamide adenine dinucleotide	NAD+	Activates sirtuins, prevents energetic depletion	2000	Sigma-Aldrich (N1511)	(31-33)
$\alpha$ -tocopherol	TOC	Antioxidant	100	Sigma (T3251)	(27, 34)
$\beta$ -Carotene	BCAR	Antioxidant	0.19	Sigma (C9750)	(35)
Butylated hydroxyanisole	BHA	Antioxidant	139	Aldrich (B1253)	(36, 37)
Butylated hydroxytoluene	BHT	Antioxidant	113	Aldrich (B1378)	(37)
( $\pm$ )-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid	Trolox <sup>TM</sup>	Antioxidant	150	Aldrich (238813)	(28)
3,4-dihydro-5-[4-(1-piperidinyl)butoxy]-1(2H)-isoquinolinone	DPQ	Inhibitor of PARP1	10	Sigma (D5314)	(33)
L-mimosine	Lmim	Inhibits G1-S cell cycle transition	175	Calbiochem (475842)	(38, 39)
NG-Monomethyl-D-arginine	NMMA	Nitric oxide synthase inhibitor	20	Sigma (M7033)	(40, 41)
NG-Nitro-L-arginine-methyl ester	LNAME	Nitric oxide synthase inhibitor	300	Sigma (N5751)	(28)
Ethyleneglycol-O,O'-bis(2-amino ethyl)-N,N,N',N'-tetraacetic acid	EGTA	Divalent ion chelator	2000	Sigma (E3889)	(27, 42)
Cycloheximide	CHX	Protein synthesis inhibitor	1.5	Sigma (C7698)	(43, 44)
Actinomycin D	ActD	RNA synthesis inhibitor	0.002	Sigma (A1410)	(44, 45)
Digoxin	Dig	Na <sup>+</sup> /K <sup>+</sup> ATPase inhibitor	0.13	Sigma (D6003)	(46, 47)
Deferoxamine	Deferox	Chelates iron	152	Calbiochem (252750)	(36)
1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene	U0126	Mek 1/2 inhibitor	13.1	Alexis (ALX-270-237)	(48)
Anthra(1,9-cd)pyrazol-6(2H)-one 1,9-Pyrazoloanthrone	SP600125	JNK inhibitor	10	Alexis (ALX-270-339)	(49)
Necrostatin-1	Nec-1	Inhibitor of necroptosis	19	Sigma (N9037)	(50)
Cyclosporin A	CspA	Binds cyclophilin	5.0	Sigma (C3662)	(51, 52)
Aurintricarboxylic Acid	ATA	Nuclease inhibitor	38	Sigma (A1895)	(53, 54)

Tumor protein 53	p53	Initiates apoptosis in response to DNA damage			(55, 56)
Beclin-1	Bec1	Required for autophagy			(57)
B-cell leukemia/lymphoma 2	Bcl2	Prevents mitochondrial outer membrane permeabilization			(58, 59)
Survivin	Survivin	Inhibits caspases			(60-62)

## Supplementary Table 2: Characterized Lethal compounds

Details of the names, abbreviations, concentrations, suppliers, and mechanism of action (and literature support for that mechanism) of the characterized lethal compounds used.

Lethal Compound	Abbr ev	Mechanism	[Highest] $\mu\text{M}$	Supplier (cat#)	References
Irinotecan	IRN	Topoisomerase-I-mediated DNA damage	210	Sigma (I1406)	(63-65)
Camptothecin	CPT	Topoisomerase-I-mediated DNA damage	8.6	Sigma (C9911)	(66-71)
Doxorubicin	Doxo	Topoisomerase-II-mediated DNA damage	34	Sigma (D1515)	(12, 72-74)
Daunorubicin	Dauno	Topoisomerase-II-mediated DNA damage	35	Sigma-Aldrich (D8809)	(74, 75)
Mitoxantrone	Mitox	Topoisomerase-II-mediated DNA damage	5.8	Sigma (M6545)	(76-78)
Etoposide	Etop	Topoisomerase-II-mediated DNA damage	570	Sigma (E1383)	(79-81)
Podophyllotoxin	PDTX	Tubulin depolymerizer	2.4	Fluka (81125)	(82-84)
Vinblastine	Vblast	Tubulin depolymerizer	0.22	Sigma (V1377)	(84-87)
Vincristine	Vchrist	Tubulin depolymerizer	0.76	Sigma (V8388)	(84, 87-89)
Colchicine	Colch	Tubulin depolymerizer	3.3	Fluka (27650)	(90-93)
Echinomycin	ECH	Bis-DNA intercalator	0.18	Fluka (44659)	(94, 95)
Cycloheximide	CHX	Translational Inhibitor	142	Sigma (C7698)	(43)
Rotenone	Rot	Mitochondrial complex I inhibitor	200	Sigma (R8875)	(96-99)
2,4 dinitrophenol	2,4 DNP	Uncouples oxidative phosphorylation	11000	Aldrich (D198501)	(100, 101)
Valinomycin	Val	Ionophore and mitochondrial uncoupler	1.2	Fluka (94675)	(102-104)
Sodium Azide	NaN <sub>3</sub>	Mitochondrial complex IV inhibitor	120000	Fluka (71289)	(105-107)
Staurosporine	STS	Kinase inhibitor	4.0	Sigma (S6942)	(108-111)
H7	H7	Kinase inhibitor	570	Calbiochem (371955)	(112, 113)
Chlorambucil	ChlB	Alkylation agent	5300	Sigma (C0253)	(114, 115)
Carmustine	Carm	Alkylation agent	2700	Sigma (C0400)	(116, 117)
Semustine	Sem	Alkylation agent	2700	Sigma (S4026)	(118, 119)
Lomustine	Lom	Alkylation agent	5300	Sigma (L5918)	(120, 121)
MG132	MG132	Proteasome inhibitor	2.3	Sigma (C2211)	(122, 123)
MG262	MG262	Proteasome inhibitor	0.10	Boston Biochem (I-120)	(124, 125)
Bortezomib	Bortez	Proteasome inhibitor	0.20	Millenium Pharmaceuticals	(125, 126)
Trichostatin A	Trich A	HDAC inhibitor	10	Sigma (T8552)	(127-129)
MS-275	MS-275	HDAC inhibitor	200	Sigma (M5568)	(130, 131)
Scriptaid	Script	HDAC inhibitor	80	Biomol (GR326-0001)	(132, 133)

Supplementary Table 3: Modulatory Profiles

The modulatory profiles for all lethal compounds used (characterized and novel) are given.

Changes in potency are expressed as the log ratio of the fold change in potency.

Changes in efficacy are expressed as the fraction change in efficacy.

Parameter	Potency	Potency	Potency	Potency	Potency	Potency	
	Cell Line	BJeLR	BJeLR	BJeLR	BJeLR	BJeLR	
	Modulator	TLCK	LNAME	NAD+	NAD+/Lmim	Lmim	Gd3+
Irinotecan		0.0698	0.111	0.368	0.391	0.194	0.036
Camptothecin_1		0.0426	0.01	0.34	0.41	0.192	0.0214
Doxorubicin		0.109	0.0606	0.489	0.656	0.311	-0.00401
Daunorubicin_1		0.119	0.0179	0.461	0.618	0.238	-0.00621
Mitoxantrone		0.154	0.0611	0.421	0.59	0.314	0.0284
Etoposide		0.138	0.0654	0.376	0.483	0.267	0.0944
Podophyllotoxin		-0.0931	0.0203	0.075	0.107	0.0559	0.0889
Vinblastine_1		-0.113	0.0359	0.699	0.933	0.188	0.0136
Vincristine		0.0382	-0.0392	0.228	0.49	0.176	0.0246
Colchicine		-0.0416	-0.0415	0.169	0.176	0.11	0.049
Rotenone		-0.09	0.00761	0.261	0.485	0.148	0.0942
2,4 Dinitrophenol		-0.0479	-0.0428	0.204	0.185	-0.0116	-0.0161
Sodium Azide		0.0987	0.0411	0.249	-0.072	-0.22	0.0475
Valinomycin		-0.0675	-0.00339	0.204	0.499	0.0874	0.0355
Staurosporine		0.039	0.0249	0.894	0.659	-0.0437	0.0992
H7		-0.00516	0.00252	0.403	0.323	0.0532	6.36E-05
Erastin_1		0.0777	-0.111	-0.13	0.631	0.344	-0.0929
Chlorambucil		0.364	0.247	0.523	0.425	0.248	0.0931
Carmustine		0.0477	0.119	0.222	0.106	0.0748	0.149
Lomustine		-0.0575	0.0964	0.191	0.0487	0.029	0.095
Semustine		0.229	0.0722	0.0264	0.151	0.0806	-0.282
MG132_1		0.0201	0.126	0.114	0.265	0.101	0.00178
MG262		0.041	0.0709	0.195	0.37	0.218	0.0508
Bortezomib		0.0904	0.0151	0.278	0.415	0.178	-0.0016
TrichostatinA		0.0454	-0.0551	0.147	0.251	0.239	0.0234
MS275		0.115	0.0243	0.442	0.547	0.205	0.076
Scriptaid		-0.0255	0.0219	0.254	0.576	0.317	0.0205
RSL3		0.968	0.122	0.036	1.33	1.49	0.0148
NPC25		0.0603	0.117	-0.0946	0.247	0.523	-0.0208
NPC26		-0.0143	0.0528	0.253	0.18	-0.000418	0.0277
Camptothecin_2		0.0274	0.173	0.458	0.47	0.339	0.0938
NPC1		-0.0652	0.0436	0.133	0.159	0.0476	0.102
NPC2		-0.00721	0.0503	0.0476	0.187	0.144	0.0237
NPC4		0.114	0.146	-0.165	0.274	0.782	0.063
NPC5		-0.0189	0.0899	0.0585	0.13	0.0896	0.0368
NPC6		-0.0245	0.046	0.0286	-0.115	-0.2	0.0701
NPC7		-0.0819	0.0651	-0.00205	0.989	0.544	0.0113
NPC8		-0.136	0.206	0.118	0.21	0.0653	0.13
NPC10		-0.0638	0.128	0.0726	0.165	0.0868	0.0178
NPC11		0.0452	0.1	0.0566	0.141	0.0655	0.0435
NPC12		0.0565	-0.0349	0.139	-0.083	0.0878	0.152
Vinblastine_2		0.00266	0.159	-0.0105	0.146	0.611	0.0332
MG132_2		-0.0604	0.0402	0.078	0.212	0.122	0.065
Cycloheximide		0.107	0.00665	0.174	0.3	0.289	0.094
Erastin_2		0.39	0.0497	0.168	1.6	1.2	0.13
NPC14		0.0484	0.0719	0.0502	-0.0536	-0.0395	0.036
NPC15		0.147	0.11	0.0569	0.0803	0.0778	0.0726
Daunorubicin_2		0.245	0.0365	0.457	0.621	0.499	-0.123
NPC17		0.0216	0.0755	0.0336	-0.0254	0.225	0.0551
NPC18		0.000216	0.0511	0.179	0.153	0.0941	0.0149
NPC19		-0.0667	-0.0178	0.0446	0.0349	0.084	0.0441
NPC20		0.0132	0.0281	0.074	0.205	0.222	0.0306
NPC21		0.0543	0.0427	0.267	0.339	0.278	0.042
NPC22		-0.0544	0.0119	0.064	0.0287	0.0405	0.0324
NPC23		0.00572	0.0663	0.197	0.39	0.366	0.0241
NPC27		-0.108	-0.033	0.19	-0.0906	-0.17	0.00484
Echinomycin		-0.00684	0.0549	0.744	0.782	0.334	0.0278
NPC28		-0.0159	0.0303	0.0108	0.186	0.0668	0.0224

Parameter	Potency	Potency	Potency	Potency	Potency	Potency
Cell Line	BJeLR	BJeLR	BJeLR	BJeLR	BJeLR	BJeLR
Modulator	Co2+	3MA	NMMA	Cycloheximide	ALLN	Pepstatin
Irinotecan	0.141	-0.297	-0.0142	0.493	0.405	0.193
Camptothecin_1	0.177	-0.37	-0.0102	0.609	0.311	0.0814
Doxorubicin	0.897	0.0887	-0.0436	0.586	0.225	0.0434
Daunorubicin_1	0.879	-0.0195	-0.0958	0.616	0.284	0.137
Mitoxantrone	2.08	-0.122	0.0578	0.83	0.465	0.0985
Etoposide	0.466	-0.324	-0.129	0.582	0.432	0.0981
Podophyllotoxin	-0.0514	-0.113	-0.0345	0.141	-0.0755	0.025
Vinblastine_1	1.05	-0.39	-0.152	1.1	-0.304	0.0244
Vincristine	0.72	-0.253	-0.0237	0.642	-0.122	0.0263
Colchicine	0.33	-0.0121	0.00759	0.255	-0.0642	0.0113
Rotenone	0.575	-0.124	0.0255	0.868	-0.0044	0.15
2,4 Dinitrophenol	0.032	-0.0586	-0.0265	1.23	-0.0217	-0.00331
Sodium Azide	0.00703	-0.534	0.00173	0.343	0.0538	0.031
Valinomycin	0.178	0.04	-0.0491	3.05	0.103	0.0358
Staurosporine	0.179	-0.158	0.05	0.325	0.186	0.121
H7	-0.0964	-0.016	0.00462	0.184	-0.103	0.0376
Erastin_1	-0.651	0.296	-0.266	0.355	-0.12	0.455
Chlorambucil	0.12	-0.722	0.0387	0.521	0.187	0.00677
Carmustine	0.0268	-0.198	0.0665	0.375	-0.107	-0.00217
Lomustine	0.077	-0.285	0.0515	0.858	-0.194	-0.0301
Semustine	-0.175	-0.355	0.0967	0.392	-0.212	0.0552
MG132_1	0.419	0.0284	0.0217	0.748	-0.93	0.0135
MG262	0.243	-0.0704	0.0152	0.779	-0.545	0.0174
Bortezomib	0.662	0.0773	0.0149	1.46	-0.274	0.0663
TrichostatinA	0.908	0.0346	-0.0358	0.91	-0.239	-0.0201
MS275	0.532	-0.0153	0.048	0.876	-0.168	0.0114
Scriptaid	0.428	0.0143	0.0269	1.01	-0.286	-0.0183
RSL3	0.206	0.368	0.0588	0.519	0.0533	0.00599
NPC25	0.292	-0.189	-0.0375	1.25	-0.0354	0.0509
NPC26	-0.164	0.123	-0.0792	0.458	-0.915	0.0927
Camptothecin_2	0.121	-0.326	0.00292	0.469	0.414	0.0517
NPC1	0.274	0.141	0.065	0.159	-0.104	0.0753
NPC2	0.0849	0.0388	0.0348	0.298	-0.708	0.0585
NPC4	0.702	-0.17	0.0643	2.47	-0.0562	0.0448
NPC5	-0.13	-0.0556	0.0209	0.172	-0.076	0.0232
NPC6	-0.162	-0.161	0.0197	0.232	-0.00665	0.076
NPC7	0.447	-0.177	0.0358	1.12	-0.0641	-0.00523
NPC8	-0.471	-0.188	0.0455	0.478	-0.78	-0.0703
NPC10	0.0658	0.0309	0.0449	0.27	-0.243	0.0683
NPC11	0.0378	-0.00188	0.0667	0.208	-0.0512	0.103
NPC12	-0.121	-0.118	-0.0301	0.458	-0.245	0.106
Vinblastine_2	0.918	-0.227	0.0187	0.601	-0.396	0.00752
MG132_2	0.34	0.029	0.0467	0.793	-1.06	0.0334
Cycloheximide	0.887	0.143	0.0199	1.49	0.375	0.136
Erastin_2	-0.414	0.534	-0.0396	1.12	0.0165	0.0292
NPC14	-0.12	0.089	0.0582	0.0355	-0.125	-0.0135
NPC15	0.0464	-0.0511	0.0921	0.21	-0.138	0.077
Daunorubicin_2	0.891	-0.0556	-0.0474	0.418	0.124	0.0602
NPC17	-0.0396	0.0225	0.0367	0.277	-0.196	0.00416
NPC18	0.247	-0.0514	0.0812	0.506	-0.258	0.0403
NPC19	-0.128	-0.0377	0.0222	0.247	-0.372	-0.0599
NPC20	0.133	0.084	0.0569	0.198	-0.947	0.0222
NPC21	0.296	-0.143	0.0538	0.92	-0.412	0.199
NPC22	0.0373	-0.0788	0.0612	0.087	-0.758	0.0607
NPC23	0.487	0.293	0.141	0.46	-0.13	0.0578
NPC27	0.00195	-0.151	0.0995	0.163	-0.0792	-0.0762
Echinomycin	0.164	1.46	0.0403	0.449	0.0808	0.0925
NPC28	0.158	0.0242	0.0302	0.136	-0.393	0.0462

Parameter	Potency	Potency	Potency	Potency	Potency	Potency
Cell Line	BJeLR	BJeLR	BJeLR	BJeLR	BJeLR	BJeLR
Modulator	ZVAD	BOCD	TOC	TroloX	Necrostatin-1	DPQ
Irinotecan	0.291	0.225	0.121	0.0355	0.0128	-0.0293
Camptothecin_1	0.26	0.231	0.139	0.133	0.0813	-0.124
Doxorubicin	0.168	0.13	0.101	0.0425	-0.0304	0.0197
Daunorubicin_1	0.207	0.178	0.0467	-0.155	-0.143	-0.0738
Mitoxantrone	0.206	0.159	0.192	-0.16	-0.124	-0.285
Etoposide	0.19	0.242	-0.0451	-0.151	-0.251	-0.199
Podophyllotoxin	0.0576	-0.0936	0.0623	-0.0258	-0.14	-0.156
Vinblastine_1	-0.049	-0.0688	0.795	-0.0848	-0.217	-0.0522
Vincristine	0.00118	-0.0606	0.208	-0.191	-0.246	-0.158
Colchicine	0.102	-0.0272	-0.014	-0.0661	-0.0905	-0.0879
Rotenone	0.174	-0.113	0.33	0.00681	-0.184	-0.109
2,4 Dinitrophenol	-0.0315	0.0495	0.0198	0.00774	-0.138	-0.145
Sodium Azide	0.00287	-0.0126	0.0131	-0.094	-0.0771	-0.114
Valinomycin	0.186	0.0822	1.17	0.0212	-0.0466	-0.087
Staurosporine	0.403	0.36	1.01	-0.0779	-0.0372	-0.0546
H7	0.0471	0.0552	0.0297	0.0783	0.022	0.0354
Erastin_1	0.0617	-0.0153	1.34	0.874	0.528	-0.12
Chlorambucil	0.111	0.069	0.0674	0.0318	-0.00872	0.0506
Carmustine	0.0714	0.0649	0.0706	0.0544	0.0179	0.00627
Lomustine	0.0386	0.0589	0.0188	0.0178	0.0567	0.0461
Semustine	-0.0001	-0.00605	0.0215	0.0143	0.0242	-0.0373
MG132_1	-0.368	0.0108	0.12	0.00475	-0.122	0.0235
MG262	-0.234	0.0451	0.221	-0.0257	-0.0489	-0.0351
Bortezomib	0.00259	0.0292	0.0875	0.0587	0.0967	0.00256
TrichostatinA	0.215	0.115	0.0145	-0.0286	-0.0124	0.0267
MS275	0.282	0.229	0.0675	0.00346	-0.0552	0.0346
Scriptaid	0.303	0.0179	0.042	-0.0467	0.0187	0.0643
RSL3	0.0113	0.125	1.41	1.33	0.917	0.0996
NPC25	0.0944	0.00541	0.123	0.217	0.0642	0.0255
NPC26	-0.0377	-0.0323	0.179	0.388	0.124	0.0111
Camptothecin_2	0.133	0.103	-0.0379	0.0703	0.127	-0.0997
NPC1	-0.0181	0.136	0.116	0.0676	0.0349	-0.0182
NPC2	0.021	0.0368	0.0169	0.0121	0.0152	0.0273
NPC4	0.139	-0.0114	0.0812	-0.00113	0.0391	0.0609
NPC5	-0.0109	0.00819	-0.00505	0.0493	0.0226	0.0364
NPC6	0.0113	-0.00834	0.041	0.0169	0.0138	-0.011
NPC7	0.0417	-0.0673	0.0415	0.0268	-0.0668	0.0919
NPC8	-0.00208	0.0119	0.0475	-0.0766	0.0637	-0.0123
NPC10	-0.0382	0.0796	0.144	0.0136	0.0728	-0.0748
NPC11	0.0236	0.0762	0.145	0.057	0.0768	-0.0541
NPC12	0.00988	0.051	0.0735	0.0322	0.0285	0.0956
Vinblastine_2	-0.158	-0.0159	0.547	0.026	-0.0387	0.024
MG132_2	-0.451	0.0681	0.164	-0.00353	-0.0859	-0.0186
Cycloheximide	0.0536	0.0711	-0.00555	0.0427	0.0709	0.133
Erastin_2	-0.123	-0.0252	1.44	0.964	0.827	0.0473
NPC14	0.0462	0.0543	-0.0428	-0.00632	0.0061	-0.00388
NPC15	0.0508	0.0896	-0.00107	-0.0472	-0.0228	-0.0149
Daunorubicin_2	0.06	0.113	0.000199	-0.0133	0.00529	-0.0329
NPC17	0.0431	-0.0263	0.00775	0.0368	0.0153	0.0622
NPC18	0.0334	-0.065	0.025	-0.0268	0.0963	-0.0102
NPC19	0.00711	0.00914	0.0419	-0.0605	-0.0554	-0.0191
NPC20	-0.0136	0.0464	0.088	0.00426	0.0276	0.0134
NPC21	0.204	-0.0621	0.0466	-0.0498	-0.0474	0.0351
NPC22	0.0355	0.0638	0.132	-0.058	-0.0254	-0.00222
NPC23	0.0267	0.0994	0.238	0.0591	0.0426	0.0363
NPC27	-0.0916	0.0141	-0.00405	-0.0212	-0.0371	0.075
Echinomycin	-0.0879	0.0835	0.693	-0.0585	0.042	-0.0298
NPC28	0.0293	0.0296	0.0722	0.0133	0.0168	-0.00767

Parameter	Potency	Potency	Potency	Potency	Potency	Potency
Cell Line	HT1080	HT1080	HT1080	HT1080	HT1080	HT1080
Modulator	p53	Beclin-1	ZVAD	BOCD	ALLN	Pepstatin
Irinotecan	0.242	0.0888	0.183	0.227	-0.151	0.0753
Camptothecin_1	0.441	0.0559	0.16	0.161	0.147	0.0365
Doxorubicin	-0.000666	-0.0369	0.0862	0.0917	0.06	0.058
Daunorubicin_1	0.0932	-0.0329	0.1	0.112	-0.0806	0.0805
Mitoxantrone	-0.0114	-0.0421	0.106	0.243	0.192	0.0929
Etoposide	-0.013	-0.18	0.122	0.328	0.222	-0.0148
Podophyllotoxin	0.0761	-0.00393	0.0283	0.0653	0.184	0.0204
Vinblastine_1	0.229	-0.0427	-0.066	0.102	0.176	0.0359
Vincristine	0.121	-0.116	0.0463	0.168	0.344	0.0306
Colchicine	-0.0983	-0.121	0.108	0.05	0.0699	0.0258
Rotenone	0.292	-0.0104	0.206	0.04	0.977	0.0247
2,4 Dinitrophenol	0.172	0.204	0.12	0.186	0.107	0.128
Sodium Azide	0.0689	-0.187	0.00843	0.0267	0.116	0.0142
Valinomycin	0.659	0.0262	-0.403	-0.352	0.0425	-0.412
Staurosporine	0.0109	-0.0401	0.0178	0.276	-0.619	0.0672
H7	-0.0459	-0.0303	0.0592	0.0641	-0.252	0.000866
Erastin_1	0.0363	0.0302	-0.17	0.0709	-0.15	-0.0637
Chlorambucil	-0.00181	0.00329	0.0496	0.0458	-0.0954	-0.0328
Carmustine	0.0415	-0.0503	-0.0482	-0.013	-0.215	-0.00524
Lomustine	0.0542	-0.0819	0.0036	0.0106	-0.266	0.0174
Semustine	0.115	-0.13	0.00668	0.0612	-0.195	0.00908
MG132_1	0.282	0.184	-0.388	0.0615	-0.692	-0.0718
MG262	0.0912	-0.0688	-0.298	-0.00264	-0.487	0.00668
Bortezomib	0.12	0.0241	-0.146	-0.00689	-0.3	0.021
TrichostatinA	0.115	-0.0817	0.0373	0.0693	-0.499	0.0174
MS275	0.241	-0.101	0.00352	0.0345	-0.537	0.00167
Scriptaid	0.125	-0.0515	-0.00927	0.00797	-0.55	-0.0156
RSL3	-0.0547	0.0544	0.0748	0.0106	-0.22	-0.094
NPC25	0.302	0.0737	0.201	0.237	0.453	0.0449
NPC26	0.0471	0.266	0.112	0.144	-0.875	-0.0543
Camptothecin_2	0.752	1.15	0.134	0.257	0.0588	0.0875
NPC1	0.0191	0.0286	0.0936	0.0773	-0.201	0.0496
NPC2	0.065	0.181	0.0562	0.0733	-0.835	0.0341
NPC4	0.265	0.0668	0.0603	-0.0245	0.477	-0.00686
NPC5	0.0286	0.00688	-0.209	0.0227	-0.433	0.0648
NPC6	-0.0833	0.154	-0.0651	-0.00942	-0.222	0.0759
NPC7	0.426	0.0925	0.212	0.0608	-0.319	0.0385
NPC8	0.192	0.111	0.0702	0.034	-0.764	0.000187
NPC10	0.014	0.047	0.0432	0.0497	-0.39	0.0272
NPC11	0.00354	0.0895	0.00507	0.0363	-0.206	0.0105
NPC12	-0.106	0.0588	-0.0297	0.00481	-0.491	0.013
Vinblastine_2	0.254	0.0429	-0.0287	0.117	0.334	-0.0246
MG132_2	0.154	0.175	-0.527	0.0288	-1.14	0.00083
Cycloheximide	-0.165	0.205	0.0775	0.123	1.06	0.0411
Erastin_2	0.212	0.0602	-0.103	0.106	-0.473	0.0103
NPC14	-0.015	0.0508	0.0316	-0.00456	-0.255	0.0319
NPC15	-0.002	0.0441	-0.0197	-0.0445	-0.334	-0.0724
Daunorubicin_2	0.058	0.0487	0.125	0.0454	-0.0453	-0.00834
NPC17	0.0275	-0.00874	0.006	0.0236	-0.171	0.133
NPC18	-0.104	0.0723	-0.03	-0.0365	-0.491	0.00861
NPC19	0.134	0.228	-0.0274	-0.0408	-0.475	0.0456
NPC20	0.0309	0.000232	0.0255	0.0427	-0.999	0.0175
NPC21	0.119	-0.0218	0.0323	0.00758	-0.967	0.0227
NPC22	0.0995	0.128	0.025	0.0502	-0.725	0.0879
NPC23	0.0222	0.0876	0.0303	0.0926	-0.303	0.0352
NPC27	-0.0341	0.0754	-0.0959	0.0229	-0.119	0.0544
Echinomycin	0.0311	0.0104	-0.0401	0.0612	-0.158	-0.00154
NPC28	0.134	0.199	0.0451	0.129	-0.443	0.0416

Parameter	Potency	Potency	Potency	Potency	Potency	Potency
Cell Line	HT1080	HT1080	HT1080	HT1080	HT1080	HT1080
Modulator	DPQ	TOC	Bcl2	Survivin	U0126	Trolox
Irinotecan	0.0408	0.151	0.263	0.128	0.143	0.0762
Camptothecin_1	0.0457	0.0683	0.324	0.128	0.0633	0.08
Doxorubicin	0.0788	0.114	0.222	0.101	0.11	-0.0335
Daunorubicin_1	0.0886	0.179	0.283	0.138	0.0854	0.0561
Mitoxantrone	0.0326	0.284	0.376	0.484	-0.00303	-0.027
Etoposide	0.0531	0.0251	0.559	0.319	-0.0693	0.122
Podophyllotoxin	0.031	0.0105	0.0548	0.0398	0.0104	-0.00253
Vinblastine_1	-0.0113	0.858	0.126	0.129	-0.0602	-0.0172
Vincristine	0.0487	0.239	0.12	0.163	0.196	-0.0794
Colchicine	0.0405	0.0172	0.0822	0.0759	0.436	0.0199
Rotenone	0.00958	0.352	0.0732	0.0939	0.0954	-0.0239
2,4 Dinitrophenol	0.287	0.389	0.259	0.268	-0.242	0.289
Sodium Azide	-0.00816	-0.00724	0.137	0.132	0.0353	-0.051
Valinomycin	1.93	1.82	1.94	1.94	-0.0904	0.194
Staurosporine	0.0368	1.01	0.389	0.14	-0.529	-0.197
H7	0.0344	0.0798	0.137	0.0459	-0.0712	0.00677
Erastin_1	0.253	1.14	0.0842	0.0722	1.4	0.821
Chlorambucil	-0.0063	-0.0521	0.103	0.0425	-0.0542	-0.0491
Carmustine	-0.0163	0.0134	0.102	0.0846	0.0491	-0.00335
Lomustine	-0.0075	-0.0255	0.128	0.109	-0.046	-0.0374
Semustine	0.00348	-0.0112	0.0783	0.0867	-0.041	-0.0811
MG132_1	-0.0867	0.282	0.102	0.173	-0.212	-0.0245
MG262	0.0193	0.237	0.0712	0.0828	-0.202	-0.0587
Bortezomib	0.049	0.0515	0.127	0.111	-0.0196	0.0318
TrichostatinA	0.0112	0.0285	0.237	0.178	-0.239	-0.0844
MS275	0.00917	0.0355	0.138	0.0994	-0.0876	-0.105
Scriptaid	0.0143	0.00412	0.135	0.0961	-0.138	-0.124
RSL3	0.506	1.56	0.0548	0.0502	1.67	1.63
NPC25	0.0237	0.0508	0.0195	-0.00432	0.0406	0.0293
NPC26	-0.0261	0.355	0.0271	0.0573	0.0309	-0.000728
Camptothecin_2	0.0795	0.072	0.321	0.22	0.397	0.108
NPC1	0.0293	0.098	0.00687	0.014	-0.0542	0.0386
NPC2	0.000225	0.072	0.028	0.0305	-0.0456	0.00181
NPC4	-0.00323	0.00286	0.00291	0.0283	0.254	-0.0355
NPC5	0.0259	0.0121	0.0452	0.128	0.0194	-0.0136
NPC6	0.0431	0.0258	0.0741	0.143	0.166	0.0374
NPC7	-0.00478	-0.0257	0.0522	0.0767	0.0973	0.0025
NPC8	0.0595	0.173	-0.0391	0.0638	0.167	-0.0542
NPC10	0.0984	0.191	-0.0463	0.0111	-0.117	-0.00503
NPC11	0.0116	0.0708	-0.00656	0.063	-0.00801	0.094
NPC12	5.41E-05	-0.0475	-0.0294	0.0896	0.151	0.0139
Vinblastine_2	0.0358	0.677	0.0613	0.0592	-0.0535	-0.0202
MG132_2	0.0139	0.257	-0.00365	0.0432	-0.0821	-0.0159
Cycloheximide	0.062	0.148	0.0481	0.221	0.257	0.0975
Erastin_2	0.108	1.71	0.000468	0.0765	1.31	1.35
NPC14	-0.0374	-0.0358	0.0987	0.173	-0.0189	0.052
NPC15	-0.093	-0.014	0.0933	0.0814	0.0359	0.0444
Daunorubicin_2	-0.00649	0.0488	0.0451	0.111	0.158	0.0723
NPC17	0.104	0.147	0.028	0.0901	0.152	-0.0305
NPC18	-0.00894	0.0169	0.109	0.0564	0.0286	0.0126
NPC19	0.0101	-0.000195	0.0474	0.0697	0.0333	-0.0399
NPC20	0.0268	0.054	0.0029	0.00475	-0.0387	-0.0157
NPC21	0.00752	0.00349	0.0298	0.0254	0.0561	-0.0427
NPC22	-0.0032	0.165	-0.00651	0.0319	-0.0986	-0.0528
NPC23	0.0119	0.274	0.0268	0.0384	-0.176	0.0169
NPC27	-0.0034	0.122	0.0119	0.0277	0.0604	-0.00415
Echinomycin	0.0708	0.752	0.0406	0.026	0.156	-0.163
NPC28	-0.0029	0.0372	0.067	0.0399	-0.0639	0.032

Parameter	Potency	Potency	Potency	Potency	Potency	Potency
Cell Line	HT1080	HT1080	HT1080	HT1080	HT1080	HT1080
Modulator	Digoxin	BCAR	BHA	BHT	ActD	Necrostatin-1
Irinotecan	0.551	0.0652	0.157	-0.324	-0.31	0.185
Camptothecin_1	0.838	0.0232	0.263	-0.318	-0.44	0.117
Doxorubicin	0.272	0.0503	0.107	-0.0184	-0.254	0.0286
Daunorubicin_1	0.406	0.0491	0.087	-0.098	-0.245	0.0888
Mitoxantrone	0.357	0.0464	0.124	-0.00369	0.0244	0.0575
Etoposide	0.593	0.0218	0.282	-0.0262	-0.393	0.0505
Podophyllotoxin	0.184	0.0172	0.103	-0.18	-0.0125	0.064
Vinblastine_1	0.348	-0.0154	-0.105	-0.249	0.224	-0.063
Vincristine	0.361	0.0643	-0.0747	-0.326	0.255	0.0608
Colchicine	0.335	0.0652	0.115	-0.261	0.057	0.0643
Rotenone	0.374	0.0361	-0.0192	0.0754	0.184	0.0406
2,4 Dinitrophenol	-0.342	0.0289	-0.423	-0.524	0.00886	0.127
Sodium Azide	0.114	0.0416	-0.117	-0.534	0.205	-0.0864
Valinomycin	0.0317	-0.18	-0.398	-0.761	-0.0304	-0.284
Staurosporine	-0.709	-0.0836	-0.468	-0.768	0.0646	-0.293
H7	-0.0621	0.00275	-0.109	-0.578	-0.202	-0.0302
Erastin_1	0.0772	-0.015	0.886	0.889	-0.0195	0.194
Chlorambucil	0.13	0.0287	0.0017	-0.29	-0.0549	-0.0265
Carmustine	0.0609	-0.000516	0.0451	-0.362	-0.0932	-0.0707
Lomustine	-0.0495	-0.0433	-0.0445	-0.386	-0.184	-0.162
Semustine	0.0661	0.00512	-0.0186	-0.258	-0.0386	-0.0329
MG132_1	0.404	0.0268	-0.394	-0.285	-0.0146	-0.161
MG262	0.122	-0.046	-0.245	-0.287	-0.00823	-0.0813
Bortezomib	0.312	-0.0206	-0.0818	-0.28	-0.0223	-0.0527
TrichostatinA	-0.296	-0.0836	-0.177	-0.453	-0.287	-0.147
MS275	-0.759	-0.0994	-0.0788	-0.514	-0.47	-0.0373
Scriptaid	-0.279	-0.0384	-0.13	-0.286	-0.272	-0.049
RSL3	-0.421	-0.0706	1.53	1.21	-0.157	0.363
NPC25	0.226	0.00913	0.114	0.0451	0.0942	0.0445
NPC26	0.0636	-0.00519	0.0588	-0.151	0.0584	0.0422
Camptothecin_2	0.777	-0.06	0.394	-0.335	-0.101	0.28
NPC1	-0.125	-0.0248	-0.235	-0.693	0.0281	0.0242
NPC2	-0.0788	-0.00225	-0.212	-0.254	0.143	0.00957
NPC4	0.408	0.0407	0.299	-0.229	0.0663	0.294
NPC5	-0.000761	-0.0197	0.0373	-0.33	0.0157	0.00877
NPC6	0.00372	0.0237	0.192	-0.66	0.19	0.0847
NPC7	0.216	-0.0165	0.114	-0.246	0.119	0.0544
NPC8	0.0203	-0.00952	-0.0466	-0.429	0.267	0.147
NPC10	-0.0298	0.0135	-0.508	-0.571	0.201	-0.00397
NPC11	-0.0799	-0.0596	-0.471	-0.519	0.174	0.06
NPC12	0.00243	-0.0126	0.00328	-0.146	0.117	0.0976
Vinblastine_2	0.155	0.0458	-0.0749	-0.156	0.155	-0.0552
MG132_2	0.178	-0.0627	-0.454	-0.155	0.0809	-0.0725
Cycloheximide	0.0973	0.0304	0.276	-0.231	0.23	0.207
Erastin_2	0.113	-0.141	1.2	1.08	-0.00706	0.379
NPC14	-0.0879	-0.000391	0.0193	-0.288	-0.0936	0.0321
NPC15	0.0997	-0.0329	0.0265	-0.396	0.0963	0.0447
Daunorubicin_2	0.323	-0.0163	0.0891	-0.165	-0.0624	0.197
NPC17	-0.116	-0.0238	0.0416	-0.581	0.0716	0.129
NPC18	-0.0279	-0.0209	0.0203	-0.625	-0.00562	0.0644
NPC19	0.00268	-0.00938	0.00205	-0.372	-0.0366	0.0112
NPC20	-0.0828	-0.00234	-0.263	-0.381	-0.00286	-0.0179
NPC21	-0.206	0.000775	0.0421	-0.792	-0.0509	0.0281
NPC22	-0.114	-0.0224	-0.296	-0.291	0.128	-0.00564
NPC23	-0.156	-0.0161	-0.486	-0.428	0.0298	0.00562
NPC27	-0.192	0.00299	0.0989	-0.455	0.0872	0.202
Echinomycin	0.167	0.0439	-0.00474	-0.268	0.0133	0.0848
NPC28	-0.223	0.00293	-0.301	-0.359	0.0714	0.0662

Parameter	Potency	Potency	Potency	Potency	Potency	Potency
Cell Line	HT1080	HT1080	HT1080	HT1080	HT1080	HT1080
Modulator	ATA	TLCK	LNAME	NAD+	Gd3+	Co2+
Irinotecan	0.0606	0.141	0.0369	0.213	0.0852	0.282
Camptothecin_1	0.0905	0.224	0.0602	0.233	0.0624	0.624
Doxorubicin	0.154	0.264	0.0466	0.252	0.0505	0.603
Daunorubicin_1	0.0489	0.315	-0.0279	0.273	0.0138	0.463
Mitoxantrone	0.0973	0.266	0.0573	0.606	0.0935	1.48
Etoposide	-0.17	0.831	0.047	0.171	0.153	1.48
Podophyllotoxin	0.0839	0.053	-0.00702	0.0618	-0.00537	0.172
Vinblastine_1	0.0791	-0.235	-0.0438	0.323	-0.0376	1.42
Vincristine	0.193	-0.245	0.00145	0.391	0.00709	1.06
Colchicine	0.147	-0.19	0.0332	0.177	0.004	0.301
Rotenone	0.125	-0.173	0.00701	0.382	0.00117	1.62
2,4 Dinitrophenol	-0.196	0.122	0.0222	0.287	-0.0348	0.385
Sodium Azide	0.0318	0.0556	-0.0555	0.158	-0.0799	0.336
Valinomycin	-0.65	-0.127	-0.225	1.38	-0.137	-0.491
Staurosporine	-0.285	-0.291	-0.0647	0.442	-0.00211	0.18
H7	-0.0733	-0.0575	-0.0259	0.378	0.0213	-0.366
Erastin_1	-0.422	0.471	-0.0111	-0.0599	-0.0414	-0.606
Chlorambucil	-0.116	-0.046	0.00504	0.345	-0.00414	-0.0341
Carmustine	0.000785	-0.0865	0.00424	-0.0297	-0.0692	-0.399
Lomustine	0.0457	0.0644	0.00409	0.093	-0.0702	-0.00879
Semustine	0.201	0.0525	-0.0305	-0.0802	-0.119	-0.395
MG132_1	0.118	-0.0228	0.0225	0.15	0.196	-0.0143
MG262	0.156	0.017	0.0118	0.187	-0.0471	-0.0217
Bortezomib	0.26	0.0886	0.018	0.435	-0.139	0.41
TrichostatinA	-0.0598	-0.117	0.0545	0.0666	-0.0507	0.107
MS275	0.0564	-0.0738	0.0295	-0.0519	-0.0687	-0.316
Scriptaid	-0.173	-0.205	0.0142	0.082	-0.0216	-0.339
RSL3	-0.168	1.33	-0.00267	0.0609	-0.00999	-0.735
NPC25	0.05	0.0173	0.0444	0.278	0.0471	0.172
NPC26	0.0355	0.161	0.169	0.252	0.155	-0.175
Camptothecin_2	-0.274	0.0885	-0.00455	0.35	0.0744	0.0911
NPC1	-0.0387	-0.0925	0.036	0.0307	0.0439	0.0335
NPC2	0.214	-0.0218	0.0124	0.113	0.0158	0.0967
NPC4	0.0387	-0.182	0.0681	0.114	-0.0254	-0.0121
NPC5	0.0653	0.038	-0.0013	-0.0146	0.0269	-0.418
NPC6	-0.0284	0.038	0.0161	-0.0831	0.0715	-0.341
NPC7	0.0289	-0.00452	0.0271	0.277	0.0601	-0.0255
NPC8	-0.0286	-0.138	0.00698	0.0931	0.0413	-0.372
NPC10	-0.0299	0.0106	0.00621	0.0556	0.00754	0.012
NPC11	-0.0173	-0.0036	0.0208	0.0416	0.0046	-0.00778
NPC12	0.0406	0.0239	0.0112	0.0314	-0.0125	-0.116
Vinblastine_2	0.0935	-0.0492	0.0215	0.314	0.0522	0.0957
MG132_2	0.027	-0.0904	-0.00382	0.0939	0.0254	0.0665
Cycloheximide	-0.118	0.126	0.0446	0.371	0.0359	0.299
Erastin_2	-0.295	0.411	0.0605	0.0292	-0.063	-0.841
NPC14	0.0242	-0.0159	0.0689	-0.0259	0.0374	-0.409
NPC15	0.201	0.0442	0.106	0.081	-0.0976	0.0184
Daunorubicin_2	-0.0156	0.00455	0.00297	0.0933	0.00357	0.304
NPC17	0.129	0.011	0.0341	-0.0154	0.1	-0.29
NPC18	-0.0234	0.062	0.061	0.0176	0.0129	-0.27
NPC19	-0.0199	0.00205	0.0174	0.0994	0.015	-0.218
NPC20	0.029	-0.0494	-0.0102	-0.00267	-0.00103	0.00955
NPC21	-0.0139	0.0519	0.0711	0.0771	0.031	-0.266
NPC22	0.0823	-0.087	0.00754	0.0542	0.0159	-0.00142
NPC23	0.0413	-0.0352	0.0342	0.0127	0.021	0.0123
NPC27	0.139	-0.0893	0.0994	0.125	-0.0317	-0.0773
Echinomycin	0.136	0.0232	0.059	0.616	0.0385	0.0212
NPC28	-0.0546	-0.042	0.0744	0.0675	0.0458	0.078

Parameter	Potency	Potency	Potency	Potency	Potency	Potency
Cell Line	HT1080	HT1080	HT1080	HT1080	HT1080	HT1080
Modulator	3MA	NMMA	Lmim	Cycloheximide	Deferox	EGTA
Irinotecan	0.131	0.0523	0.3	0.518	0.528	0.0778
Camptothecin_1	0.111	0.0903	0.296	0.438	0.687	0.117
Doxorubicin	0.161	0.0853	0.214	0.226	0.0702	0.0148
Daunorubicin_1	0.12	0.0846	0.203	0.183	0.0728	0.0661
Mitoxantrone	0.172	0.109	0.199	0.199	0.226	0.115
Etoposide	0.096	0.0928	0.16	0.647	0.5	0.155
Podophyllotoxin	-0.0971	0.0625	0.0887	0.00143	2.26	-0.0791
Vinblastine_1	0.109	-0.0236	0.117	0.0248	3.09	0.0314
Vincristine	0.169	-0.00773	0.208	0.121	2.61	0.0371
Colchicine	-0.00503	0.00649	0.0814	-0.0654	2.43	0.00413
Rotenone	0.154	0.0687	0.134	0.0266	2.45	-0.0886
2,4 Dinitrophenol	-0.295	0.128	0.108	1.09	0.648	-0.332
Sodium Azide	-0.211	-0.00136	-0.17	0.132	0.27	-0.0146
Valinomycin	-0.778	-0.199	-0.691	1.65	0.959	0.112
Staurosporine	-0.496	-0.123	-0.22	-0.588	-0.395	-0.0303
H7	-0.0598	0.0131	-0.0224	-0.089	0.18	-0.0107
Erastin_1	0.095	0.0438	1.98	0.37	1.45	0.0651
Chlorambucil	-0.119	-0.146	0.00861	0.0505	-0.174	0.00953
Carmustine	-0.343	-0.00569	-0.0416	-0.0278	0.0319	-0.045
Lomustine	-0.172	-0.12	-0.103	0.0803	0.099	-0.0893
Semustine	-0.626	0.0213	-0.0277	0.112	0.0126	-0.142
MG132_1	0.27	0.0281	0.143	0.463	-0.204	0.0388
MG262	-0.0569	0.0425	0.0835	0.157	-0.171	-0.109
Bortezomib	-0.127	0.0248	0.105	0.255	0.0886	-0.00626
TrichostatinA	-0.379	0.058	-0.0395	-0.238	-0.43	-0.13
MS275	-0.389	0.00751	-0.303	-0.299	-0.668	-0.0892
Scriptaid	-0.288	-0.00958	-0.117	-0.187	-0.335	-0.039
RSL3	-0.138	0.00523	1.46	-0.036	1.58	0.144
NPC25	0.252	0.0337	0.427	0.176	1.9	0.0722
NPC26	0.349	0.0159	0.113	0.328	0.148	0.159
Camptothecin_2	-0.209	0.0239	0.221	0.419	0.653	0.0881
NPC1	-0.0262	0.00403	-0.0917	0.0415	-0.296	0.0579
NPC2	0.0326	0.03	0.139	0.204	-0.042	0.0485
NPC4	0.15	0.101	0.587	0.205	1.89	-0.01
NPC5	-0.0241	0.00526	-0.0863	0.0663	0.121	-0.0615
NPC6	-0.235	-0.019	-0.279	0.0863	0.361	0.064
NPC7	0.133	0.024	0.501	0.124	1.35	0.0157
NPC8	-0.0702	0.0173	0.203	0.329	0.359	0.0456
NPC10	0.00604	0.0101	0.0311	0.229	-0.154	0.0307
NPC11	-0.0672	0.00545	-0.0449	0.101	-0.119	0.0064
NPC12	-0.044	-0.0112	0.0384	0.206	0.383	-0.0426
Vinblastine_2	0.166	0.00964	0.475	0.0741	2.97	0.0497
MG132_2	0.0582	0.00982	0.0927	0.486	-0.307	0.0156
Cycloheximide	0.0461	0.0537	0.293	0.537	0.968	0.0647
Erastin_2	0.27	0.00181	1.66	0.542	1.43	0.0965
NPC14	-0.0911	-0.0215	-0.203	-0.173	-0.125	0.0544
NPC15	-0.1	0.0743	0.0439	0.108	0.297	0.0579
Daunorubicin_2	-0.0952	0.0515	0.122	0.0353	-0.0417	0.00449
NPC17	-0.0219	0.0138	0.0608	0.017	0.189	0.108
NPC18	-0.104	-0.0147	-0.047	0.114	0.0841	0.00964
NPC19	-0.0909	-0.0215	-0.11	0.283	0.29	0.0515
NPC20	-0.0157	0.012	-0.00698	0.147	-0.0273	0.0534
NPC21	-0.0717	-0.0177	0.046	0.529	0.154	0.0215
NPC22	-0.096	-0.00763	-0.0233	0.0372	0.0878	0.0496
NPC23	-0.012	0.0237	0.00535	0.43	-0.18	0.0619
NPC27	0.233	-0.0317	-0.0671	-0.13	0.0518	0.00657
Echinomycin	1.48	0.0217	0.208	0.159	0.139	0.0202
NPC28	-0.0175	0.0563	0.000865	0.0704	-0.299	-0.014

Parameter	Potency	Potency	Efficacy	Efficacy	Efficacy	Efficacy
Cell Line	HT1080	HT1080	BJeLR	BJeLR	BJeLR	BJeLR
Modulator	SP600125	CspA	TLCK	LNAME	NAD+	NAD+/Lmim
Irinotecan	0.0361	-0.594	NaN	0.0022	0.0635	0.056
Camptothecin_1	0.115	-0.701	0.029	0.00689	0.111	0.109
Doxorubicin	-0.0997	-0.389	0.0236	-0.00578	0.101	0.077
Daunorubicin_1	0.00948	-0.194	0.0106	0.00384	0.0651	0.0566
Mitoxantrone	-0.00911	-0.404	0.00112	-0.000877	0.0615	0.0628
Etoposide	0.0417	-0.761	NaN	NaN	0.0547	0.0746
Podophyllotoxin	-0.198	-0.367	0.0026	-0.0037	0.147	0.177
Vinblastine_1	0.0375	-0.439	0.0014	0.0056	0.167	0.211
Vincristine	0.0101	-0.681	-0.0168	-0.0111	0.146	0.171
Colchicine	-0.0929	-0.392	0.002	-0.0033	0.146	0.188
Rotenone	-0.0971	-0.594	0.00381	-0.0263	0.126	0.227
2,4 Dinitrophenol	-0.504	-0.718	0.0576	-0.0269	0.12	0.135
Sodium Azide	-0.0362	-0.178	0.013	0.0045	0.0613	0.0885
Valinomycin	-0.463	-0.702	0.0456	-0.0134	0.101	0.104
Staurosporine	-0.562	-0.456	NaN	0.00242	NaN	0.255
H7	-0.0965	-0.287	0.00202	-0.00206	0.0764	0.113
Erastin_1	-0.0496	0.18	0.0122	1.45E-08	0.0364	0.149
Chlorambucil	-0.13	-0.36	-0.00273	0.00147	0.0068	0.0481
Carmustine	-0.0814	-0.714	-3.54E-05	0.00171	0.00202	0.0042
Lomustine	0.0556	-0.377	0.00728	0.00382	0.0328	0.0902
Semustine	-0.25	-0.657	0.00158	-0.00031	0.0189	0.0337
MG132_1	0.149	-1.14	0.00566	0.00193	0.0637	0.0716
MG262	-0.261	-0.961	0.0111	0.00668	0.0692	0.0577
Bortezomib	-0.082	-0.79	0.0129	0.00601	0.0691	0.0693
TrichostatinA	-0.315	-0.496	0.0107	0.00276	0.114	0.156
MS275	-0.426	-0.823	0.012	0.0107	0.123	0.161
Scriptaid	-0.213	-0.526	0.0234	0.0115	0.148	0.149
RSL3	-0.486	-0.483	NaN	0.00577	0.0322	0.0333
NPC25	0.143	-0.0209	-0.000907	0.0081	0.15	0.24
NPC26	0.51	-0.0855	0.00351	0.00528	0.0506	0.0643
Camptothecin_2	0.317	-0.499	0.00171	0.00309	0.0969	0.137
NPC1	-0.00971	-0.152	-4.05E-05	5.63E-05	0.00171	0.00329
NPC2	0.00738	-0.0159	0.000353	0.000521	-1.01E-05	0.0137
NPC4	0.267	-0.206	-0.0381	0.00151	0.122	0.301
NPC5	-0.0188	-0.0875	0.00139	0.00127	0.0186	0.0111
NPC6	0.134	-0.226	-0.0117	0.00665	-0.0164	-0.0195
NPC7	0.126	-0.115	-0.00496	0.0271	0.165	0.242
NPC8	-0.0758	-0.622	0.00631	0.00255	NaN	NaN
NPC10	-0.0243	-0.0216	0.000162	6.98E-06	0.000306	0.013
NPC11	-0.00398	-0.0276	0.00246	-0.00036	0.00901	0.00999
NPC12	0.0114	-0.0327	0.00445	-0.0137	0.00641	0.0378
Vinblastine_2	0.181	-0.226	-0.00479	0.0192	0.114	0.188
MG132_2	0.0336	-0.736	-0.00428	-0.000367	0.0371	0.0432
Cycloheximide	-0.0206	0.181	0.0109	0.00475	0.0883	0.111
Erastin_2	0.111	0.0707	0.00406	-0.00469	0.0178	NaN
NPC14	-0.0764	-0.125	-0.00161	-0.000673	0.00423	0.00675
NPC15	-0.076	-0.12	0.0193	0.0106	0.0202	0.0232
Daunorubicin_2	0.149	-0.135	-0.0288	0.011	0.0491	0.102
NPC17	0.0148	-0.19	0.00335	0.00535	0.0207	0.0475
NPC18	0.0379	-0.434	-0.00359	-0.00342	0.00483	-0.0012
NPC19	-0.00836	-0.226	0.00486	-0.00402	0.0043	0.0115
NPC20	0.0237	-0.0015	0.00187	0.00233	0.00729	0.0143
NPC21	0.0155	-0.391	0.00343	0.00336	NaN	NaN
NPC22	-0.0085	0.00628	0.00246	0.000699	0.0228	0.021
NPC23	-0.0383	-0.0487	-0.00337	-0.0151	-0.00371	0.00318
NPC27	0.093	-0.0716	0.0014	0.00202	0.131	0.172
Echinomycin	0.36	-0.409	-0.00103	0.00111	0.0942	0.0994
NPC28	-0.0377	-0.0355	5.86E-05	0.00128	0.0048	0.0109

Parameter	Efficacy	Efficacy	Efficacy	Efficacy	Efficacy	Efficacy
Cell Line	BJeLR	BJeLR	BJeLR	BJeLR	BJeLR	BJeLR
Modulator	Lmim	Gd3+	Co2+	3MA	NMMA	Cycloheximide
Irinotecan	0.00164	0.00365	-0.00224	NaN	0.00263	0.00286
Camptothecin_1	0.00654	0.00158	0.0143	NaN	-0.00316	0.0168
Doxorubicin	0.00416	-0.0106	-0.0082	0.00822	-0.00782	0.0712
Daunorubicin_1	0.00144	-0.000653	-0.00309	0.0345	-0.000853	0.0348
Mitoxantrone	-0.00126	0.000211	0.045	NaN	-0.000768	0.000241
Etoposide	NaN	-0.000874	0.00166	0.00723	NaN	0.0579
Podophyllotoxin	0.0605	-0.0023	0.192	-0.0197	-0.0051	0.216
Vinblastine_1	0.0737	0.0151	0.13	-0.00398	0.000123	0.224
Vincristine	0.0416	-0.00428	0.118	-0.0345	-0.00297	0.192
Colchicine	0.0738	-0.0036	0.19	-0.0112	-0.0085	0.231
Rotenone	0.174	0.00345	-0.0198	0.0115	0.0156	NaN
2,4 Dinitrophenol	-0.0313	-0.0149	0.0593	0.0347	-0.0192	0.772
Sodium Azide	0.0161	0.00186	NaN	0.0407	0.00148	0.0027
Valinomycin	-0.0213	-0.0064	0.0863	0.012	-0.0172	0.499
Staurosporine	0.0317	-0.00482	NaN	NaN	0.000261	NaN
H7	0.0169	0.0108	-0.0353	0.00669	-0.00815	0.053
Erastin_1	0.101	5.95E-09	4.81E-07	-4.47E-10	1.26E-07	-4.47E-10
Chlorambucil	-0.00423	0.00124	-0.00445	NaN	NaN	-0.00282
Carmustine	0.00128	-9.73E-05	NaN	0.00313	-0.00156	0.00714
Lomustine	0.0303	0.0106	0.0809	-0.0115	-0.00202	NaN
Semustine	0.00522	0.00126	0.00313	NaN	0.00426	0.0259
MG132_1	0.00733	0.00372	0.0256	-0.00746	0.000461	0.461
MG262	0.0158	0.0023	0.0482	-0.0152	0.00432	0.364
Bortezomib	0.0237	0.00262	0.0806	-0.017	0.00105	0.422
TrichostatinA	0.0276	0.00755	0.0398	-0.00481	-0.00141	0.305
MS275	0.00974	0.0117	0.0706	0.00208	0.00512	0.223
Scriptaid	0.0281	0.0115	0.0204	-0.0125	0.00222	NaN
RSL3	-0.0162	0.00242	0.0673	0.00214	0.00259	0.0123
NPC25	0.131	0.0262	0.322	0.0244	0.00746	0.397
NPC26	0.0126	0.00392	-0.00359	-0.00315	-0.0106	0.189
Camptothecin_2	0.0126	0.00112	0.0282	NaN	0.00158	0.0942
NPC1	0.000308	0.000582	0.00251	0.00212	0.000561	0.0014
NPC2	-0.00337	0.00182	0.0025	-0.000523	-0.000561	-0.00329
NPC4	0.123	0.00365	0.244	-0.0097	-0.0152	0.403
NPC5	0.00204	0.00154	0.0152	-7.44E-05	-7.44E-05	-7.44E-05
NPC6	-0.00862	0.00304	-0.0125	0.00239	0.00342	0.0364
NPC7	0.103	0.0421	0.135	0.0175	0.0143	0.301
NPC8	NaN	0.000988	0.0407	NaN	NaN	NaN
NPC10	0.00118	4.29E-07	0.00268	0.00031	0.00306	3.92E-05
NPC11	0.000257	0.000759	0.00623	0.00133	6.19E-06	0.000398
NPC12	0.0276	-0.00065	0.0303	0.00871	0.00805	-0.005
Vinblastine_2	0.11	0.0512	0.297	-0.0172	-0.00531	0.301
MG132_2	0.00587	-0.00457	0.0287	-0.00367	0.00364	0.419
Cycloheximide	0.036	0.0137	0.199	0.00679	0.001	0.251
Erastin_2	0.17	-0.00518	0.0128	-0.00143	0.00475	0.0588
NPC14	0.00124	0.000625	0.00776	-0.00172	-0.00194	0.00124
NPC15	-0.00865	0.00944	0.0241	-0.00467	-0.00914	-0.0109
Daunorubicin_2	0.0509	-0.00925	0.0591	0.0609	0.000795	0.257
NPC17	0.00104	0.00235	-0.0034	0.00422	0.00488	-0.00628
NPC18	-0.0114	0.00706	NaN	0.0302	-0.0173	NaN
NPC19	0.0128	-0.00028	0.0253	-0.00054	0.00254	-0.0169
NPC20	-0.00138	0.00243	0.00267	-0.00142	-0.00292	-0.00243
NPC21	-0.0151	-0.01	NaN	0.0471	0.00445	NaN
NPC22	0.00147	0.00129	0.00719	-0.000651	-0.000792	0.00243
NPC23	-0.00263	-0.0058	-0.0154	-0.0023	0.00136	0.00476
NPC27	-0.00664	0.00181	-0.00189	-0.00395	-0.000911	0.0165
Echinomycin	0.0158	-0.00168	0.104	NaN	-0.00518	0.194
NPC28	0.00138	0.000953	0.00118	-0.00172	0.000801	0.00251

Parameter	Efficacy	Efficacy	Efficacy	Efficacy	Efficacy	Efficacy
Cell Line	BJeLR	BJeLR	BJeLR	BJeLR	BJeLR	BJeLR
Modulator	ALLN	Pepstatin	ZVAD	BOCD	TOC	Trolox
Irinotecan	0.00463	-0.00196	0.113	0.0873	0.00261	-0.00198
Camptothecin_1	0.018	-1.85E-05	0.0979	0.0916	-0.00348	-0.0044
Doxorubicin	0.0298	0.0111	0.0799	0.0648	0.0136	-0.0133
Daunorubicin_1	0.00174	0.000538	0.0457	0.0389	0.00272	-0.00632
Mitoxantrone	0.00399	-7.58E-05	0.0629	0.0584	0.0046	0.0048
Etoposide	0.187	0.0043	0.0946	0.0742	0.0171	-0.0035
Podophyllotoxin	0.0278	0.0198	0.0947	0.0695	0.00665	-0.0188
Vinblastine_1	0.0107	-0.00678	0.0812	0.0523	-0.0215	-0.00373
Vincristine	0.027	-0.0148	0.0682	0.0417	0.0178	-0.0157
Colchicine	0.00925	0.0131	0.096	0.0619	-0.00095	-0.0143
Rotenone	-0.00335	0.022	0.0841	0.0439	0.0276	-0.00727
2,4 Dinitrophenol	-0.0372	0.139	0.0211	0.0256	0.172	0.108
Sodium Azide	-0.00376	NaN	0.0297	0.0191	NaN	NaN
Valinomycin	-0.0384	0.0581	0.0146	0.015	0.0448	0.0535
Staurosporine	-0.00497	NaN	NaN	NaN	NaN	0.000715
H7	-0.0149	0.0106	0.102	0.0817	0.0124	-0.000832
Erastin_1	-2.83E-07	0.165	-5.51E-07	0.00248	NaN	NaN
Chlorambucil	NaN	NaN	NaN	NaN	-0.000177	-0.00275
Carmustine	0.0016	0.000211	9.71E-05	0.00011	0.00102	-0.000337
Lomustine	0.00423	-0.00321	-0.00443	-0.00065	-0.00318	-0.0139
Semustine	0.000335	-0.00057	-0.000449	-0.000316	-0.000146	-9.81E-05
MG132_1	-0.001	0.00175	0.0424	0.0512	-0.00317	-0.00667
MG262	-0.00554	0.00271	0.0534	0.0529	-0.00045	-0.00259
Bortezomib	-0.00617	-0.00052	0.0444	0.0476	0.00305	-0.00351
TrichostatinA	-0.00659	-0.00273	0.165	0.141	0.00017	-0.00526
MS275	0.00313	0.00182	0.219	0.122	0.00883	0.00331
Scriptaid	-0.0049	-0.00793	0.145	0.0952	-0.000378	-0.00345
RSL3	-0.00168	0.00166	0.000295	0.000439	0.00884	0.00116
NPC25	0.00655	0.00945	0.0859	0.0541	-0.0151	-0.0173
NPC26	-0.0205	-0.00371	0.0322	0.0317	0.00161	0.00518
Camptothecin_2	NaN	-0.00116	0.112	0.103	0.00362	0.0017
NPC1	-0.000239	0.000106	0.00222	-2.35E-05	-0.00212	-0.00325
NPC2	0.00154	0.0011	-0.000394	0.00306	0.00461	0.00119
NPC4	0.019	-0.0105	0.0348	0.0036	-0.0363	-0.00275
NPC5	-0.000285	0.00112	-0.000446	0.000739	0.00121	0.00129
NPC6	-0.00571	0.00111	-0.00618	-0.00927	0.00379	0.00336
NPC7	-0.0176	0.0193	0.0631	0.0348	0.0337	0.000976
NPC8	-0.000869	0.000275	NaN	NaN	NaN	0.00483
NPC10	4.20E-05	-8.08E-06	8.72E-05	0.000247	1.03E-05	-4.16E-07
NPC11	-1.19E-06	4.14E-07	1.61E-05	-1.03E-06	-0.00025	-1.93E-05
NPC12	-0.000345	-0.000627	-0.000456	-0.000594	0.0169	0.00139
Vinblastine_2	0.00515	0.00408	0.0695	0.0385	-0.0205	0.00682
MG132_2	-0.0062	0.00199	0.0368	0.045	0.000481	-0.00256
Cycloheximide	0.0484	0.000947	0.036	0.0405	-0.00351	-0.00152
Erastin_2	0.00827	-0.00525	-0.00336	-0.000868	0.2	0.0927
NPC14	0.00205	0.000455	0.00347	-3.03E-08	-0.0019	-0.00306
NPC15	0.000898	-0.00364	-0.000404	-0.00347	0.0115	0.00394
Daunorubicin_2	0.00375	-0.00569	0.0854	0.062	-0.00278	-0.00504
NPC17	0.00698	-3.71E-08	-0.00175	-0.00484	-0.00248	0.000585
NPC18	0.0321	-0.0258	0.00251	0.0154	-0.00434	-0.00669
NPC19	-0.00214	0.00182	0.00145	0.00755	0.00129	-0.00254
NPC20	0.00218	0.000367	0.000698	0.000514	0.00141	-0.000916
NPC21	0.0472	0.00974	0.0164	0.0203	0.00478	-0.00303
NPC22	-0.000358	0.000371	0.000826	0.00103	0.00129	0.00111
NPC23	0.013	-6.19E-05	-2.75E-05	-6.75E-05	-0.0102	-0.0121
NPC27	-0.00142	-0.00194	0.0063	0.000479	0.00298	-0.00433
Echinomycin	0.0112	-0.0111	0.0802	0.0795	0.0072	-0.00266
NPC28	0.00316	2.06E-06	4.14E-07	0.000434	0.0031	0.000402

Parameter	Efficacy	Efficacy	Efficacy	Efficacy	Efficacy	Efficacy
Cell Line	BJeLR	BJeLR	HT1080	HT1080	HT1080	HT1080
Modulator	Necrostatin-1	DPQ	p53	Beclin-1	ZVAD	BOCD
Irinotecan	0.000842	0.00228	NaN	NaN	0.137	NaN
Camptothecin_1	-0.00396	-0.00229	0.19	0.00299	NaN	NaN
Doxorubicin	-0.0103	-0.011	NaN	NaN	NaN	NaN
Daunorubicin_1	-0.00444	-0.00152	NaN	NaN	NaN	NaN
Mitoxantrone	-0.00243	NaN	NaN	-0.00586	0.0492	0.055
Etoposide	NaN	NaN	0.154	NaN	0.0857	NaN
Podophyllotoxin	-0.0189	-0.00855	0.13	-0.036	0.172	0.167
Vinblastine_1	-0.0135	-0.00683	0.139	-0.0325	0.167	0.19
Vincristine	-0.0226	0.0279	0.146	-0.0274	0.193	0.185
Colchicine	-0.0122	0.00525	0.16	-0.0253	0.193	0.182
Rotenone	0.0466	0.0311	0.161	-0.0683	0.139	0.176
2,4 Dinitrophenol	0.146	0.0125	0.0303	NaN	0.138	0.136
Sodium Azide	NaN	0.0498	NaN	NaN	0.00848	-0.00208
Valinomycin	0.0479	-0.0259	0.156	0.147	0.13	0.22
Staurosporine	NaN	0.000311	NaN	0.000682	0.179	0.168
H7	-0.0156	0.00551	0.00522	-0.0833	0.0978	0.0985
Erastin_1	1.42E-07	6.37E-07	-9.09E-06	0.00389	5.59E-05	0.00107
Chlorambucil	0.000103	0.000762	0.0033	-0.0112	0.000115	-0.000107
Carmustine	-0.000723	-0.000641	-0.000736	0.000844	0.003	0.0018
Lomustine	0.00428	-0.00645	1.09E-06	0.00408	0.00427	0.00168
Semustine	-0.000177	-0.000185	-3.23E-05	-0.000316	0.00172	0.00213
MG132_1	-0.000888	-0.000455	0.05	-0.00237	0.135	0.109
MG262	0.00599	0.00309	0.0171	-0.00158	0.142	0.0865
Bortezomib	0.00792	0.00732	0.0669	-0.0061	0.139	0.111
TrichostatinA	-0.00037	0.00396	0.0292	0.00335	0.112	0.0839
MS275	0.0112	0.00408	0.0224	0.00497	0.0958	0.0753
Scriptaid	0.00485	0.00191	0.0218	0.00444	0.151	0.116
RSL3	-0.0105	0.00959	-0.000196	0.000819	-0.000239	-8.30E-05
NPC25	0.0148	-0.002	0.159	0.0836	0.247	0.22
NPC26	-0.00365	-0.00397	0.000773	0.00409	-0.00271	0.000874
Camptothecin_2	-0.00085	0.0035	0.34	0.284	0.119	0.105
NPC1	-0.00333	-0.0016	0.000357	0.00135	-0.000266	-0.000285
NPC2	-0.000665	-0.000659	0.000104	7.68E-05	-0.000551	0.00164
NPC4	0.0113	-0.0124	0.239	-0.00335	0.219	0.152
NPC5	-0.000825	-0.000447	0.000637	-0.00102	0.000364	-5.85E-06
NPC6	0.00722	-0.00597	NaN	0.0186	0.00489	NaN
NPC7	0.0422	0.00177	0.128	0.0116	0.24	0.257
NPC8	-0.00151	0.000877	0.0351	0.0116	0.00812	NaN
NPC10	-7.91E-07	5.88E-07	-0.000121	0.000909	-0.000827	0.000742
NPC11	-0.00025	9.55E-05	0.000308	0.00109	-0.000272	0.000898
NPC12	0.00994	-0.00542	-0.000231	-0.00169	0.012	0.0125
Vinblastine_2	0.0224	0.00565	0.198	-0.00095	0.268	0.231
MG132_2	-0.000849	-0.00152	0.0459	0.00725	0.212	0.152
Cycloheximide	0.0101	0.00448	0.028	-0.000847	0.0642	0.0661
Erastin_2	0.0605	-0.00131	0.00715	0.0047	0.000494	-0.000217
NPC14	0.0013	-0.00166	-0.000365	-0.0019	-0.0007	-0.000382
NPC15	0.00737	0.000142	2.35E-06	0.0015	-0.00254	-0.00182
Daunorubicin_2	-0.00207	-0.00272	NaN	NaN	NaN	NaN
NPC17	0.0058	-0.00529	0.000139	0.00212	-0.000222	-0.00167
NPC18	-0.0107	-0.00515	0.00478	0.00675	0.00233	0.0249
NPC19	-0.00274	-0.00375	0.0026	0.0067	0.0105	0.00783
NPC20	-0.00173	-0.0025	0.000685	0.000223	-0.000481	0.00166
NPC21	0.013	0.00871	-0.172	-0.0625	-0.0428	0.0018
NPC22	0.000416	-4.00E-06	-0.000307	0.000565	0.000653	0.0021
NPC23	-0.0152	-0.00842	0.00228	0.00197	-0.00101	-0.00242
NPC27	-0.00434	0.00342	0.000508	0.00343	0.00294	-0.000228
Echinomycin	-0.00304	0.00869	0.0675	-0.0806	0.157	0.13
NPC28	0.000358	1.50E-05	0.000566	0.000603	-0.000724	0.00243

Parameter	Efficacy	Efficacy	Efficacy	Efficacy	Efficacy	Efficacy
Cell Line	HT1080	HT1080	HT1080	HT1080	HT1080	HT1080
Modulator	ALLN	Pepstatin	DPQ	TOC	Bcl2	Survivin
Irinotecan	NaN	NaN	NaN	0.152	NaN	0.0983
Camptothecin_1	NaN	0.00455	NaN	0.00245	0.145	0.0434
Doxorubicin	NaN	NaN	NaN	NaN	NaN	NaN
Daunorubicin_1	NaN	NaN	NaN	NaN	NaN	NaN
Mitoxantrone	0.114	0.0131	0.0135	NaN	0.0317	NaN
Etoposide	NaN	NaN	NaN	NaN	0.0725	NaN
Podophyllotoxin	0.225	-0.0155	-0.0077	-0.0179	0.054	0.0495
Vinblastine_1	0.242	-0.02	0.0127	-0.0202	0.0605	0.0312
Vincristine	0.257	0.00255	0.0105	-0.00075	0.0585	0.0197
Colchicine	0.252	0.00695	0.00865	-0.00655	0.0458	0.0255
Rotenone	NaN	-0.0238	-0.0074	-0.0196	0.0358	0.0481
2,4 Dinitrophenol	0.0149	0.0659	0.0588	0.143	0.23	0.0425
Sodium Azide	-0.00308	0.00383	NaN	NaN	NaN	NaN
Valinomycin	0.213	0.188	0.318	0.273	0.307	0.319
Staurosporine	0.0717	0.00193	0.000728	NaN	NaN	0.00403
H7	0.0463	0.0127	0.0209	0.0187	0.0845	0.088
Erastin_1	0.000722	-0.000308	0.0027	0.433	7.21E-05	-1.75E-05
Chlorambucil	-0.000106	0.00017	0.000159	0.0199	0.00952	0.0336
Carmustine	0.000149	-3.37E-15	-2.83E-15	0.00584	-0.000256	0.00193
Lomustine	4.40E-05	9.19E-05	-2.40E-05	0.0125	-0.00319	-0.00131
Semustine	0.000488	-0.000945	-0.00215	-8.50E-05	-0.00374	-0.0048
MG132_1	-0.00591	-0.00942	0.00799	0.0313	0.031	0.00897
MG262	-0.00638	-0.00237	0.0121	-0.00131	0.0551	0.0103
Bortezomib	-0.00661	-0.0016	0.0111	-0.000359	0.055	0.00857
TrichostatinA	-0.0166	0.00241	0.00276	-0.00523	0.066	-0.0123
MS275	NaN	-0.00683	0.00207	0.00211	0.0428	0.00323
Scriptaid	-0.00366	0.00518	-2.33E-06	0.0138	0.0705	0.00526
RSL3	-0.00925	-0.00578	0.0243	0.0219	0.000366	0.00221
NPC25	0.119	0.00705	0.012	-0.00515	0.0487	0.0277
NPC26	-0.0139	0.00335	0.00471	-0.00475	-0.000977	-0.00709
Camptothecin_2	NaN	NaN	0.00038	-0.0024	0.186	NaN
NPC1	-0.000278	-0.000285	-0.000281	0.000195	-0.00097	-0.000119
NPC2	0.0031	-0.000557	-0.000558	0.00212	-0.000501	-0.000355
NPC4	0.127	-0.00435	-0.0109	-0.0119	0.0383	0.0154
NPC5	0.00234	0.000356	-8.99E-06	0.0118	0.000191	-0.00102
NPC6	0.0373	0.0137	0.0181	0.0287	0.00437	NaN
NPC7	-0.0458	0.0209	0.0356	0.0972	-0.00391	0.0118
NPC8	NaN	0.00673	0.0234	NaN	0.00645	0.00328
NPC10	0.000179	-0.000732	-0.000827	0.000855	3.47E-05	0.000834
NPC11	0.000702	5.00E-06	8.44E-05	0.0025	-0.000648	-0.000141
NPC12	NaN	0.0155	-0.00646	0.225	-0.00738	0.00381
Vinblastine_2	0.154	0.0047	0.0182	0.0227	0.0447	0.0257
MG132_2	0.0035	0.00182	0.00499	0.0105	0.0177	-0.000841
Cycloheximide	0.227	0.00831	0.032	0.0106	0.0238	0.00339
Erastin_2	NaN	-8.31E-05	-4.16E-05	NaN	6.46E-05	-0.00199
NPC14	0.00872	-0.000627	0.00207	0.00348	-0.000414	0.00213
NPC15	0.0183	0.00282	-0.000894	0.0244	0.00152	-0.000813
NPC17	NaN	NaN	NaN	NaN	NaN	NaN
NPC18	0.00735	0.00191	-0.000805	0.0152	-0.00183	-0.00105
NPC19	0.083	0.00214	0.00165	0.0176	0.000609	0.00315
NPC20	0.0552	0.00198	0.000572	0.0396	-0.00409	-0.00123
NPC21	NaN	0.000988	-3.15E-05	0.000268	7.95E-05	5.38E-05
NPC22	0.127	0.0218	0.0334	0.0537	0.0152	-0.0241
NPC23	0.00167	0.000503	1.72E-05	-0.000161	-0.000193	-0.000425
NPC27	-0.00294	-0.000146	-0.000456	-0.00302	-0.00135	-0.000538
Echinomycin	-0.00347	0.00119	-0.00106	0.0101	-0.00126	-0.000354
NPC28	0.226	0.00945	0.0212	-0.164	0.00945	0.0454
	0.0046	0.00695	0.00627	0.00444	-0.00237	-0.000439

Parameter	Efficacy	Efficacy	Efficacy	Efficacy	Efficacy	Efficacy
Cell Line	HT1080	HT1080	HT1080	HT1080	HT1080	HT1080
Modulator	U0126	Trolox	Digoxin	BCAR	BHA	BHT
Irinotecan	-0.0294	NaN	NaN	NaN	NaN	NaN
Camptothecin_1	NaN	NaN	NaN	1.95E-05	NaN	NaN
Doxorubicin	NaN	NaN	NaN	NaN	NaN	NaN
Daunorubicin_1	NaN	NaN	NaN	NaN	NaN	NaN
Mitoxantrone	-0.0462	-0.0198	0.188	NaN	0.0402	0.0161
Etoposide	NaN	NaN	0.118	NaN	-0.000185	NaN
Podophyllotoxin	0.254	0.00599	0.162	-0.00516	0.0349	0.124
Vinblastine_1	0.251	0.00105	0.147	-0.00418	0.0229	0.133
Vincristine	0.278	0.00152	0.167	0.00438	0.0297	0.121
Colchicine	0.292	0.00504	0.155	0.00442	0.0284	0.111
Rotenone	0.176	0.00805	0.215	-0.00025	-0.00174	NaN
2,4 Dinitrophenol	0.271	0.0706	0.00636	0.14	-0.178	-0.0285
Sodium Azide	NaN	0.00188	NaN	NaN	NaN	0.0199
Valinomycin	0.0519	0.0763	-0.43	-0.0375	-0.0167	-0.114
Staurosporine	0.00108	0.00156	0.0566	0.00325	0.0114	0.0669
H7	-0.0442	0.0141	0.0432	-0.0247	-0.0404	-0.103
Erastin_1	NaN	0.289	-1.96E-05	0.00209	NaN	NaN
Chlorambucil	0.0295	-0.00344	0.00386	0.0233	0.117	0.0212
Carmustine	0.00267	0.00558	0.000313	0.00261	0.00483	0.00266
Lomustine	0.0196	0.00137	0.00235	-0.00127	-0.00105	0.0319
Semustine	0.00562	0.00404	0.00664	0.00167	0.000155	0.00682
MG132_1	-0.0232	-0.0185	0.0553	-0.00813	-0.00545	0.00663
MG262	-0.0121	-0.0121	0.0751	0.00204	-0.00124	0.000352
Bortezomib	-0.0197	-0.0143	0.0992	-0.000932	-0.00272	0.00369
TrichostatinA	-0.0207	-0.0266	0.002	0.00123	-0.0189	0.0438
MS275	0.00336	-0.0141	0.0737	0.00941	0.00462	-0.0229
Scriptaid	0.0044	-0.00198	0.00748	0.000494	0.00238	0.0516
RSL3	0.0242	0.0491	-0.00387	0.00934	0.0547	NaN
NPC25	0.187	-0.0063	0.099	-0.0052	0.00794	0.103
NPC26	-0.00284	0.000975	-0.00197	0.00305	-0.00133	-0.00675
Camptothecin_2	NaN	NaN	0.129	NaN	0.104	NaN
NPC1	-3.37E-07	9.27E-07	0.000173	8.91E-05	0.00023	NaN
NPC2	-0.000914	0.000147	0.000272	0.000939	0.002	0.00115
NPC4	0.141	-0.0177	0.141	0.00924	0.027	NaN
NPC5	-0.00541	-0.0055	0.014	0.000436	0.00568	NaN
NPC6	-0.0191	-0.00369	0.0149	-0.0095	-0.0158	NaN
NPC7	0.0439	-0.000269	0.146	-0.00455	0.055	0.189
NPC8	0.00367	NaN	NaN	0.0039	NaN	NaN
NPC10	-0.000315	-0.000166	0.000651	0.000479	0.00298	NaN
NPC11	-0.00015	-9.90E-05	-0.00015	0.000101	0.0017	0.00458
NPC12	0.00971	0.0115	0.00741	0.00247	0.157	NaN
Vinblastine_2	0.198	-0.00739	0.136	-0.00204	0.0106	0.128
MG132_2	-0.0017	-0.00895	0.01	-0.00504	0.00243	-0.00782
Cycloheximide	-0.0161	0.00233	0.0711	0.00216	0.0428	0.0274
Erastin_2	NaN	NaN	0.00159	-5.29E-05	NaN	NaN
NPC14	-0.000673	-0.00215	-0.00211	0.000191	0.00115	-0.00171
NPC15	0.00151	0.00438	0.000338	-0.000428	0.0302	0.0377
Daunorubicin_2	NaN	NaN	NaN	NaN	NaN	NaN
NPC17	-0.000363	0.000587	-0.00216	0.00038	0.0126	0.0291
NPC18	-0.0153	-0.00872	NaN	-0.000391	NaN	NaN
NPC19	-0.00369	-0.00393	0.00827	-0.00281	0.00102	0.0168
NPC20	0.000243	0.000956	-0.000721	-0.000717	0.00155	NaN
NPC21	0.0097	-0.00128	-0.0196	0.018	0.0476	-0.0686
NPC22	-0.000766	0.000806	-0.000914	-0.000512	0.00141	-0.000533
NPC23	-0.000726	0.00104	-0.000718	-0.000458	-0.000123	-0.000542
NPC27	0.00514	-0.00153	-0.00153	0.00122	0.00495	0.000566
Echinomycin	-0.0177	0.0196	0.0858	0.0175	0.0643	0.0614
NPC28	-0.000142	-5.35E-05	0.00287	-0.000503	-0.00053	0.00297

Parameter	Efficacy	Efficacy	Efficacy	Efficacy	Efficacy	Efficacy
Cell Line	HT1080	HT1080	HT1080	HT1080	HT1080	HT1080
Modulator	ActD	Necrostatin-1	ATA	TLCK	LNAME	NAD+
Irinotecan	NaN	0.112	NaN	NaN	NaN	NaN
Camptothecin_1	NaN	NaN	NaN	-0.00462	NaN	0.32
Doxorubicin	NaN	NaN	NaN	NaN	NaN	NaN
Daunorubicin_1	NaN	NaN	NaN	NaN	NaN	NaN
Mitoxantrone	NaN	NaN	0.0693	NaN	NaN	0.25
Etoposide	NaN	NaN	NaN	NaN	NaN	0.131
Podophyllotoxin	0.102	0.0141	0.131	0.127	0.0068	0.242
Vinblastine_1	0.0841	0.00304	0.134	0.0838	0.002	0.222
Vincristine	0.0735	0.0132	0.123	0.0761	-0.0034	0.211
Colchicine	0.0938	0.0177	0.155	0.0981	0.0003	0.238
Rotenone	0.171	0.0195	0.141	0.124	-0.0129	0.222
2,4 Dinitrophenol	-0.0284	-0.0151	-0.0848	0.127	0.0117	0.299
Sodium Azide	0.0177	0.000125	NaN	0.00281	NaN	0.0168
Valinomycin	-0.0618	0.0585	0.124	0.0721	-0.15	NaN
Staurosporine	0.0249	NaN	0.00032	0.014	-0.00147	0.0803
H7	0.115	-0.0624	0.0934	0.0511	8.01E-05	0.0592
Erastin_1	0.00072	-0.00116	0.00259	0.0197	-0.00317	0.0193
Chlorambucil	0.031	0.0484	-0.000172	0.0249	0.0395	0.0814
Carmustine	0.00168	-0.000139	8.98E-05	0.004	-0.000531	0.000322
Lomustine	0.000654	0.000482	-0.00204	0.00191	-0.000666	0.0206
Semustine	0.0035	-0.0013	-0.00043	0.00401	-7.10E-05	0.0247
MG132_1	-0.0143	-0.000874	-0.00624	0.119	-0.00152	0.224
MG262	-0.0141	0.00714	0.00246	0.0816	0.000544	0.21
Bortezomib	-0.0128	0.003	-0.00136	0.116	0.0013	0.206
TrichostatinA	-0.0488	-0.00358	0.0622	0.0128	0.013	0.133
MS275	NaN	-0.00567	0.1	0.0184	0.00994	0.156
Scriptaid	-0.00807	0.00327	0.0507	0.011	0.00839	0.14
RSL3	-0.00196	0.0236	-0.00232	-0.00173	-0.00186	0.0358
NPC25	0.116	0.0362	0.0235	0.004	0.0048	0.169
NPC26	0.0133	0.000132	-0.00135	-0.011	-0.007	0.0598
Camptothecin_2	NaN	NaN	NaN	0.0191	NaN	0.0947
NPC1	0.000615	-4.71E-07	0.000117	9.62E-07	2.00E-08	0.0158
NPC2	0.00072	-0.000914	0.00087	3.93E-05	0.000311	0.0209
NPC4	0.13	0.0376	0.00802	0.00781	0.00555	0.202
NPC5	0.0051	-0.00556	0.002	0.000292	-0.000149	0.0242
NPC6	0.00727	-0.0141	0.0138	0.00915	NaN	0.0496
NPC7	0.0805	0.0356	-0.021	0.0246	0.00195	0.131
NPC8	0.0113	NaN	NaN	NaN	0.00752	NaN
NPC10	0.00197	0.000383	0.000572	-0.000473	-4.36E-05	0.0175
NPC11	8.36E-05	-0.00015	0.00157	-6.13E-06	-6.80E-06	0.0193
NPC12	0.00262	-0.000709	0.00031	0.0229	-0.00271	0.0201
Vinblastine_2	0.124	0.0294	0.0264	0.0133	0.00235	0.182
MG132_2	2.00E-05	-0.00168	0.0119	-0.00054	0.00281	0.0986
Cycloheximide	0.0532	0.00786	0.0529	0.019	0.0272	0.0583
Erastin_2	-0.000461	0.0237	0.000584	0.0111	3.27E-05	0.0187
NPC14	0.000711	0.0023	0.00166	-0.000904	0.00276	0.0306
NPC15	0.00163	-0.00042	0.00103	0.00123	0.0029	0.0217
Daunorubicin_2	NaN	NaN	NaN	NaN	NaN	NaN
NPC17	0.00321	-0.00116	0.00613	0.00747	-0.0013	0.0279
NPC18	NaN	-0.0126	0.00257	0.00709	0.00175	0.025
NPC19	0.0152	-0.00101	0.00342	0.00097	0.000242	0.0311
NPC20	0.00129	-0.000192	-0.000662	0.00152	-8.00E-05	0.0291
NPC21	0.125	0.0153	-0.014	-0.000945	0.0806	0.0215
NPC22	0.00132	0.00165	-0.000299	0.00179	-9.60E-05	0.03
NPC23	0.00219	-0.000135	-0.000223	0.000475	0.00101	0.0244
NPC27	-0.00112	0.00322	0.00625	0.00447	3.85E-05	0.124
Echinomycin	0.127	0.0128	0.0232	0.0461	0.0261	0.13
NPC28	0.00105	0.000471	-0.000585	0.0017	0.000358	0.0254

Parameter	Efficacy	Efficacy	Efficacy	Efficacy	Efficacy	Efficacy
Cell Line	HT1080	HT1080	HT1080	HT1080	HT1080	HT1080
Modulator	Gd3+	Co2+	3MA	NMMA	Lmim	Cycloheximide
Irinotecan	0.0916	NaN	0.161	NaN	0.033	0.262
Camptothecin_1	0.0532	0.211	0.279	NaN	0.138	0.065
Doxorubicin	NaN	NaN	NaN	NaN	NaN	NaN
Daunorubicin_1	NaN	NaN	NaN	NaN	NaN	NaN
Mitoxantrone	0.0201	0.349	0.0578	NaN	0.0446	0.0622
Etoposide	-0.0157	NaN	0.118	NaN	0.0685	0.206
Podophyllotoxin	0.0147	0.416	0.122	-0.0001	0.203	0.187
Vinblastine_1	-0.0002	0.414	0.15	-0.00669	0.213	0.174
Vincristine	0.0049	0.363	0.11	0.006	0.191	0.176
Colchicine	0.0073	0.395	0.132	0.00263	0.229	0.188
Rotenone	0.0116	NaN	0.138	-0.0063	0.221	0.192
2,4 Dinitrophenol	-0.0265	NaN	-0.0433	0.0373	0.128	0.45
Sodium Azide	0.00265	NaN	NaN	NaN	NaN	-0.0046
Valinomycin	0.119	NaN	NaN	NaN	-0.139	0.186
Staurosporine	0.00371	NaN	0.0258	0.00158	0.0277	0.0347
H7	0.0174	0.311	-0.0555	-0.00147	0.0475	0.0384
Erastin_1	-0.00211	0.0489	-0.00334	0.00326	NaN	0.104
Chlorambucil	0.0226	0.132	0.00126	-0.00295	0.0186	0.00961
Carmustine	-0.000519	0.00432	0.00117	0.00139	0.00596	0.00519
Lomustine	-0.00104	0.00812	0.001	0.000497	0.00269	0.0035
Semustine	0.00109	0.00593	-0.000369	0.00559	-0.000677	0.00227
MG132_1	-0.00891	0.133	0.0149	-0.00333	0.00354	0.0213
MG262	-0.00032	0.0895	0.00143	0.000262	0.00115	0.026
Bortezomib	-0.00116	0.178	-0.0039	-0.0015	0.00603	0.0366
TrichostatinA	0.0195	0.0879	-0.0318	0.00134	-0.024	0.00997
MS275	0.0142	0.0719	0.00331	-0.0018	-0.0162	-0.00423
Scriptaid	0.0111	NaN	0.023	0.000929	NaN	0.00329
RSL3	-0.000932	0.132	-0.00173	-0.00472	0.0284	-0.00392
NPC25	0.0098	0.161	0.0609	0.00426	0.241	0.186
NPC26	-0.00506	-0.00956	0.0209	-0.00206	-0.00358	0.01
Camptothecin_2	NaN	NaN	NaN	0.00194	0.145	NaN
NPC1	-3.05E-07	0.00027	8.14E-05	-1.37E-07	2.91E-05	-1.35E-07
NPC2	7.62E-05	-3.45E-05	8.84E-07	-3.85E-05	-3.85E-05	0.000845
NPC4	0.0124	0.15	0.064	-0.00077	0.303	0.213
NPC5	0.000893	0.00225	-4.99E-05	-0.000661	0.000645	0.0066
NPC6	0.00738	NaN	0.0306	0.0102	NaN	NaN
NPC7	-0.00255	0.0866	0.0319	-0.00713	0.109	0.349
NPC8	0.00254	NaN	NaN	-0.00094	0.0307	NaN
NPC10	0.000249	4.50E-09	0.000126	-1.00E-11	-1.00E-11	0.000949
NPC11	-6.80E-06	-4.76E-05	0.000896	-4.77E-05	0.000117	0.000927
NPC12	0.00393	NaN	0.000712	-0.000211	0.13	0.0016
Vinblastine_2	0.00755	0.169	0.0784	0.00141	0.27	0.246
MG132_2	0.00165	0.035	0.000497	0.00133	0.00998	0.0701
Cycloheximide	0.0023	0.161	-0.00682	0.0259	0.112	0.121
Erastin_2	-1.41E-05	0.105	0.00148	-3.23E-05	0.561	0.152
NPC14	-0.00101	-0.003	-0.00299	-0.00191	-0.00298	0.0109
NPC15	0.00195	0.000521	0.00097	-0.00013	0.0476	0.00313
Daunorubicin_2	NaN	NaN	NaN	NaN	NaN	NaN
NPC17	-0.000816	0.00247	0.00505	0.000102	0.00396	-0.000653
NPC18	-0.00176	NaN	0.0117	0.00165	0.00726	0.017
NPC19	0.0139	-0.00653	-0.00816	0.0214	0.00161	-0.00943
NPC20	-0.000423	-0.001	-0.001	-0.000928	0.000566	0.000745
NPC21	-0.00494	NaN	-0.0386	-0.0138	-0.0186	NaN
NPC22	8.20E-05	-0.00102	-0.000104	-0.00102	-0.00102	-0.000208
NPC23	0.000582	-0.00163	0.00153	0.00237	-0.000275	-0.000861
NPC27	-3.54E-05	-0.00378	-0.00446	-0.00164	-0.00349	0.0028
Echinomycin	0.0111	0.226	-0.00994	-0.00145	0.0362	0.195
NPC28	-5.79E-05	-0.000246	0.000771	-0.000429	-8.82E-05	-0.000166

Parameter	Efficacy	Efficacy	Efficacy	Efficacy
Cell Line	HT1080	HT1080	HT1080	HT1080
Modulator	Deferox	EGTA	SP600125	CspA
Irinotecan	0.172	NaN	NaN	NaN
Camptothecin_1	0.362	NaN	0.00374	NaN
Doxorubicin	NaN	NaN	NaN	NaN
Daunorubicin_1	NaN	NaN	NaN	NaN
Mitoxantrone	0.224	NaN	NaN	NaN
Etoposide	0.205	NaN	NaN	-0.0755
Podophyllotoxin	0.584	0.0328	0.00256	-0.0228
Vinblastine_1	0.505	0.018	0.00181	-0.0221
Vincristine	0.596	0.0151	0.0127	-0.0116
Colchicine	0.57	0.0205	0.00801	-0.0188
Rotenone	NaN	0.0177	-0.000799	-0.0652
2,4 Dinitrophenol	0.222	0.0104	0.0568	-0.116
Sodium Azide	0.0231	-0.00301	NaN	0.00442
Valinomycin	0.0966	NaN	-0.211	0.0785
Staurosporine	NaN	0.00205	0.024	0.0157
H7	0.254	0.0411	-0.029	-0.092
Erastin_1	NaN	0.00302	-0.000319	0.00124
Chlorambucil	0.154	0.0114	0.00839	-0.0181
Carmustine	0.026	-0.000371	-0.000811	-0.00186
Lomustine	0.0261	0.158	-0.002	0.000601
Semustine	0.00456	0.00261	0.000837	0.00306
MG132_1	0.0376	-0.00776	-0.00608	-0.00632
MG262	0.0358	-0.000799	0.00131	0.000991
Bortezomib	0.0485	0.000399	0.00057	-0.00257
TrichostatinA	0.0458	0.0105	-0.0181	-0.0379
MS275	0.128	0.019	-0.0178	-0.00955
Scriptaid	0.0859	0.00514	-0.00205	0.00675
RSL3	0.133	-0.00522	-0.00529	-0.005
NPC25	0.417	0.0379	0.0175	-0.0146
NPC26	0.0732	-0.00655	0.000546	0.00212
Camptothecin_2	0.299	NaN	NaN	NaN
NPC1	5.34E-05	-3.00E-07	-7.05E-05	-7.79E-05
NPC2	7.40E-06	-1.22E-05	0.000764	0.00119
NPC4	NaN	0.0166	0.0261	-0.00906
NPC5	0.0762	-0.000525	0.00149	0.000621
NPC6	NaN	NaN	-0.00284	-0.0068
NPC7	NaN	0.0414	0.0284	-0.0391
NPC8	0.0825	0.0316	0.0709	0.0278
NPC10	-0.000225	-0.000296	0.000453	0.00133
NPC11	0.00131	-6.80E-06	3.08E-11	7.97E-14
NPC12	0.0527	0.000618	0.00163	-0.00607
Vinblastine_2	0.452	0.0457	0.0167	-0.0251
MG132_2	0.0445	-0.00238	0.00291	-0.000408
Cycloheximide	0.29	0.028	NaN	0.0119
Erastin_2	0.448	-6.15E-05	0.00213	0.00252
NPC14	0.00164	-0.00217	0.00417	0.00268
NPC15	0.0195	-1.23E-05	0.00184	0.00191
Daunorubicin_2	NaN	NaN	NaN	NaN
NPC17	0.00673	-0.00101	0.00393	0.00234
NPC18	0.0237	0.0233	-0.00762	0.0465
NPC19	0.00214	0.0126	-0.00299	0.0148
NPC20	0.00411	0.000173	0.00224	0.00108
NPC21	0.0575	-0.0111	0.0432	-0.0659
NPC22	0.0063	-0.000644	0.00091	0.00113
NPC23	-0.000943	-0.000393	0.00122	-0.000959
NPC27	-0.00234	-0.00371	0.00199	-0.00182
Echinomycin	0.286	-0.0072	0.0101	0.00645
NPC28	0.00434	0.000693	0.000518	-0.000532

**Supplementary Table 4: Lethal Compounds Used for Gene Expression Profiling**











Information about the compounds for which gene expression data was obtained, including their EC50s in MCF7 cells, the concentration(s) used for gene expression profiling, the ratio of the concentration tested to the EC50, the number of replicates performed in MCF7 and PC3 cells, and the connectivity map instance IDs that can be used to obtain the raw data.

Compound	MCF7 EC50 ( $\mu$ M)	Conc tested ( $\mu$ M)	[Tested]/EC50	#MCF7 replicates	#PC3 replicates	Connectivity Map instance IDs
Chlorambucil	96	13	0.14	2	2	3869, 4345, 3788, 4523
Carmustine	103	100	0.97	2	1	6888, 6914, 6883
Lomustine	68	100	1.5	2	2	7045, 7089, 7050, 7094
Semustine	115	100	0.87	2	2	7487, 7540, 7492, 7545
MG132	0.98	21	22	1	0	1140
MG262	0.023	0.1	4.3	1	2	7063, 7068, 7079
Trichostatin A	0.053	0.1	1.9	5	1	331, 332, 992, 1050, 1112, 448
Trichostatin A	0.053	1	19	4	0	981, 873, 1014, 1072
Scriptaid	1.5	10	6.5	1	2	6901, 6896, 6919
Irinotecan	40	100	2.5	2	1	7498, 7530, 7535
Camptothecin	0.31	11	35	2	1	2321, 3887, 4541
Doxorubicin	0.22	7	32	2	1	3291, 5671, 4610
Daunorubicin	0.16	1	6.3	2	1	7507, 7525, 7511
Daunorubicin	0.16	7	44	1	0	4983
Mitoxantrone	0.22	8	37	2	1	3232, 5354, 6755
Etoposide	13	7	0.55	2	1	3241, 5027, 6681
Podophyllotoxin	0.013	10	790	2	1	6103, 7198, 5841
Vinblastine	0.00044	0.1	230	2	1	7517, 7551, 7556
Colchicine	0.011	0.1	9.0	1	0	644
Colchicine	0.011	10	900	2	1	3213, 5675, 4614
Rotenone	0.030	1	3.3	2	2	5915, 5943, 5920, 5948
Valinomycin	0.0047	0.1	21	2	2	5906, 5957, 5911, 5962
Staurosporine	0.41	0.01	0.025	1	0	425
Staurosporine	0.41	0.1	0.25	1	0	423
Staurosporine	0.41	1	2.5	1	0	312
H7	14	100	7.0	2	2	5936, 5963, 5941, 5968

**Supplementary Table 5: Novel Lethal Compounds**

Details of the names, suppliers, concentrations, and chemical structures of the novel lethal compounds used.

Name	Supplier (Cat#)	[Highest] μM	Structure
NPC1	Asinex (BAS 02098863)	52	
NPC2	Asinex (BAS 01365357)	46	
NPC4	Asinex (BAS 03596153)	56	
NPC5	Asinex (BAS 06262002)	61	
NPC6	Asinex (BAS 09669207)	54	
NPC7	Asinex (BAS 12662668)	56	
NPC8	Asinex (BAS 00170380)	67	
NPC10	Asinex (BAS 01307039)	62	
NPC11	Asinex (BAS 01307043)	56	
NPC12	Chembridge (5354349)	72	
NPC14	Chembridge (5468139)	60	
NPC15	Chembridge (5349968)	36	
NPC17	Interbioscreen (STOCK1N-05164)	64	
NPC18	Interbioscreen (STOCK1N-24327)	63	
NPC19	Interbioscreen (STOCK1N-17553)	52	


NPC20	Interbioscreen (STOCK1N-31157)	54	
NPC21	Interbioscreen (STOCK1N-29036)	63	
NPC22	Interbioscreen (STOCK1N-34691)	54	
NPC23	Interbioscreen (STOCK1N-01965)	68	
NPC25	Life Chemicals (F1298-0907)	57	
NPC26	Life Chemicals (F1299-0232)	46	
NPC27	Life Chemicals (F1654-0376)	56	
NPC28	Life Chemicals (F3098-0980)	49	
Erastin		73	
RSL3	Interbioscreen (STOCK1N-39651)	45	

**Supplementary Table 6: Kinase Inhibitors Tested Against NPC26**

Details of the names, targets, suppliers, concentrations tested, and the NPC26-suppressing activity of various kinase inhibitors tested.

Name	Putative Target	Supplier	Catalog#	Concentrations Tested ( $\mu$ M)	Activity
SP600125	JNK	Alexis	ALX-270-339-M005	5,10,20,40	**
Jnk Inh V	JNK	Calbiochem	420129	10	
Jnk Inh VIII	JNK	Calbiochem	420135	10, 20	
PD98059	MEK1/2	LC Labs	P-4313	2.5,5,10,20,50	*
U0126	MEK1/2	LC Labs	U-6770	10	
SB-203580	p38 MAPK	Alexis	ALX-270-179-M001	10	
SB-202190	p38 MAPK	Sigma	S7067	5	
Wortmannin	PI3K	Alexis	ALX-350-020-M001	1	
LY294002	PI3K	Alexis	ALX-270-038-M001	50	*
Y27632	ROCK	Sigma	Y0503	20	
HA1077	ROCK	Alexis	ALX-270-071-M001	50	
BIO	GSK-3	Calbiochem	361550	2	
PP2	SRC	Alexis	ALX-270-233-M001	5	
SU6656	SRC	Sigma	S9692	50	
Rapamycin	mTORC1	Sigma	R0395	1	
PP242	mTORC2	Chemdea	CD0258	5	
Go 6983	PKC	Sigma	G1918	1	
Ro 31-8220	PKC	Biomol	100004-478	5	
H89	PKA	Alexis	ALX-270-017-M001	25	
ML7	MLCK	Sigma	I2764	20	
BX 795	PDK1	Axon	Axon 11390	10	*
Akt 1/2 Inh	Akt	Sigma	A6730	2	
KN62	CaMK	Sigma	I2142	10	
Bohemine	CDK	Sigma	B0435	25	
Compound C	AMPK	Calbiochem	171260	20	
CKI-7	CK1	Sigma	C0742	25	
Alsterpaullone	GSK-3 $\beta$	Alexis	ALX-270-275-M001	5	
PS1145	IKB	Sigma	P6624	10	
CI-1033 (Canertinib)	EGFR, ERBB2	LC Labs	C-1201	2.5,5,10,20,40	** (sensitizer)
CP-690550 (Tasocitinib)	JAK3	LC Labs	C-1377	5,10,20,40	
Dasatinib	ABL1, SRC	LC Labs	D-3307	5,10,20,40	
Erlotinib	EGFR	LC Labs	E-4007	5,10,20,40	
Flavopiridol	CDK2,9	Santa Cruz	sc-202157	0.25,1,5,10,20,40	
Gefitinib	EGFR	LC Labs	G-4408	5,10,20,40	
GW-2580	cFMS	Calbiochem	344036	5,10,20,40	
GW-786034 (Pazopanib)	VEGFR2, FLT1, FLT4	LC Labs	P-6706	5,10,20,40	*
Imatinib	ABL1, KIT,	LC Labs	I-5508	5,10,20,40	

	PDGFRB				
Lapatinib	EGFR, ERBB2	LC Labs	L-4899	5,10,20,40	
MLN-518 (Tandutinib)	FLT3, KIT	LC Labs	T-7802	5,10,20,40	
PI-103	PIK3CA	Calbiochem	528100	5,10,20,40	
PKC-412 (Midostaurin)	FLT3, KIT	LC Labs	P-7600	5,10,20,40	
PTK-787 (Vatalanib)	VEGFR2	LC Labs	V-8303	5,10,20,40	
SB-431542	ALK4,5,7	Tocris Biosciences	1614	5,10,20,40	
Sorafenib	VEGFR2, BRAF	LC Labs	S-8599	0.5,1,2,5,10,20,40	**
Sunitinib	KIT, VEGFR2, FLT3	LC Labs	S-8877	1.25,2.5,5,10,20,40	
ZD-6474 (Vandetanib)	VEGFR2, EGFR, RET	LC Labs	V-9402	5,10,20,40	
VX-680 (Tozastertib)	AURKA,B,C	LC Labs	T-2304	5,10,20,40	
Reversine	MPS1 (TTK)	Sigma	R3904	1.25,2.5,5,10	

**Supplementary Table 7: SAR of NPC26**Compounds were tested in BJ-TERT/LT/ST/RAS<sup>V12</sup> cells.

Name	Group1	Group2	Group3	EC50 ( $\mu\text{g/ml}$ )	Fold Rescue (10 $\mu\text{M}$ SP600125)	Active
NPC26				0.3	6.6	***
26A8				4.2	1.4	
26A11				2.6	1.5	
26A1				0.6	2.6	*
26A2				3.8	1.8	
26A13				2.7	1.7	
26A5				10.8	1.5	
26A17				>4		
26A15				10.6		
26A6				>20		

26A3				>1.25		
26A14				0.8	7.4	***
26A10				0.7	4.1	**
26A4				3.2	1.3	
26A16				6.1	1.6	
26A9				6.5	1.9	
26A12				>4		
26A7				>1		
Ox_NPC26				0.8	4.2	**
PE_NPC26				0.3	3.0	**
SRS1-04				6.8	1.1	
SRS1-05				0.4	0.9	
SRS1-06				>12		

SRS1-39				5.3	1.1	
SRS1-78				0.2	3.3	**

## Supplementary References:

1. Oprea TI, Tropsha A, Faulon JL, & Rintoul MD (2007) Systems chemical biology. *Nature Chemical Biology* 3(8):447-450.
2. Keiser MJ, et al. (2009) Predicting new molecular targets for known drugs. *Nature* 462(7270):175-181.
3. Holliday JD, Salim N, Whittle M, & Willett P (2003) Analysis and display of the size dependence of chemical similarity coefficients. *Journal of Chemical Information and Computer Sciences* 43(3):819-828.
4. Kawase M, et al. (2002) Cell death-inducing activity of opiates in human oral tumor cell lines. *Anticancer Res* 22(1A):211-214.
5. Yang WS & Stockwell BR (2008) Synthetic Lethal Screening Identifies Compounds Activating Iron-Dependent, Nonapoptotic Cell Death in Oncogenic-RAS-Harboring Cancer Cells. *Chem Biol* 15(3):234-245.
6. Yang WS & Stockwell BR (2008) Inhibition of casein kinase 1-epsilon induces cancer-cell-selective, PERIOD2-dependent growth arrest. *Genome Biol* 9(6):R92.
7. Moffat J, et al. (2006) A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. *Cell* 124(6):1283-1298.
8. Yagoda N, et al. (2007) RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. *Nature* 447(7146):864-868.
9. Motulsky HJ & Brown RE (2006) Detecting outliers when fitting data with nonlinear regression - a new method based on robust nonlinear regression and the false discovery rate. *BMC Bioinformatics* 7:123.
10. Bridewell DJ, Finlay GJ, & Baguley BC (1999) Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II. *Cancer Chemother Pharmacol* 43(4):302-308.
11. Bridewell DJ, Finlay GJ, & Baguley BC (2001) Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA). *Anticancer Drug Des* 16(6):317-324.
12. Tewey KM, Rowe TC, Yang L, Halligan BD, & Liu LF (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. *Science* 226(4673):466-468.
13. Kaufman L & Rousseeuw PJ (1990) *Finding groups in data : an introduction to cluster analysis* (Wiley, New York) pp xiv, 342 p.
14. Lamb J, et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. *Science* 313(5795):1929-1935.
15. Hubbell E, Liu WM, & Mei R (2002) Robust estimators for expression analysis. *Bioinformatics* 18(12):1585-1592.
16. Bulinski JC, Richards JE, & Piperno G (1988) Posttranslational Modifications of Alpha-Tubulin - Detyrosination and Acetylation Differentiate Populations of Interphase Microtubules in Cultured-Cells. *Journal of Cell Biology* 106(4):1213-1220.
17. Cao Y, Charisi A, Cheng LC, Jiang T, & Girke T (2008) ChemmineR: a compound mining framework for R. *Bioinformatics* 24(15):1733-1734.

18. Hilal SH, Karickhoff SW, & Carreira LA (1995) A rigorous test for SPARC's chemical reactivity models: Estimation of more than 4300 ionization pK(a)s. *Quantitative Structure-Activity Relationships* 14(4):348-355.
19. Sensfuss U & Habicher WD (1998) 2-aminothiophenes from triacetonamine: A convenient way to novel sterically hindered piperidine derivatives. *Heteroatom Chemistry* 9(6):529-536.
20. Fearnhead HO, Dinsdale D, & Cohen GM (1995) An interleukin-1 beta-converting enzyme-like protease is a common mediator of apoptosis in thymocytes. *FEBS Lett* 375(3):283-288.
21. Sarin A, Wu ML, & Henkart PA (1996) Different interleukin-1 beta converting enzyme (ICE) family protease requirements for the apoptotic death of T lymphocytes triggered by diverse stimuli. *J Exp Med* 184(6):2445-2450.
22. Thornberry NA & Lazebnik Y (1998) Caspases: enemies within. *Science* 281(5381):1312-1316.
23. Foghsgaard L, et al. (2001) Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. *J Cell Biol* 153(5):999-1010.
24. Fearnhead HO, Rivett AJ, Dinsdale D, & Cohen GM (1995) A pre-existing protease is a common effector of thymocyte apoptosis mediated by diverse stimuli. *FEBS Lett* 357(3):242-246.
25. Jaattela M (2004) Multiple cell death pathways as regulators of tumour initiation and progression. *Oncogene* 23(16):2746-2756.
26. Deiss LP, Galinka H, Berissi H, Cohen O, & Kimchi A (1996) Cathepsin D protease mediates programmed cell death induced by interferon-gamma, Fas/APO-1 and TNF-alpha. *EMBO J* 15(15):3861-3870.
27. Tan S, Schubert D, & Maher P (2001) Oxytosis: A novel form of programmed cell death. *Curr Top Med Chem* 1(6):497-506.
28. Aarts M, et al. (2003) A key role for TRPM7 channels in anoxic neuronal death. *Cell* 115(7):863-877.
29. Stroikin Y, Dalen H, Loof S, & Terman A (2004) Inhibition of autophagy with 3-methyladenine results in impaired turnover of lysosomes and accumulation of lipofuscin-like material. *Eur J Cell Biol* 83(10):583-590.
30. Lum JJ, et al. (2005) Growth factor regulation of autophagy and cell survival in the absence of apoptosis. *Cell* 120(2):237-248.
31. Denu JM (2005) The Sir 2 family of protein deacetylases. *Curr Opin Chem Biol* 9(5):431-440.
32. Araki T, Sasaki Y, & Milbrandt J (2004) Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. *Science* 305(5686):1010-1013.
33. Ha HC & Snyder SH (1999) Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. *Proc Natl Acad Sci U S A* 96(24):13978-13982.
34. Liebler DC (1998) Antioxidant chemistry of alpha-tocopherol in biological systems. Roles of redox cycles and metabolism. *Subcell Biochem* 30:301-317.
35. Satoh K, Ida Y, Sakagami H, Tanaka T, & Fujisawa S (1998) Effect of antioxidants on radical intensity and cytotoxic activity of eugenol. *Anticancer Res* 18(3A):1549-1552.

36. Pham CG, *et al.* (2004) Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. *Cell* 119(4):529-542.
37. Williams GM, Iatropoulos MJ, & Whysner J (1999) Safety assessment of butylated hydroxyanisole and butylated hydroxytoluene as antioxidant food additives. *Food Chem Toxicol* 37(9-10):1027-1038.
38. Mosca PJ, Dijkwel PA, & Hamlin JL (1992) The plant amino acid mimosine may inhibit initiation at origins of replication in Chinese hamster cells. *Mol Cell Biol* 12(10):4375-4383.
39. Yerly-Motta V, Pavly JJ, & Herve P (1999) Screening of five specific cell cycle inhibitors using a T cell lymphoma cell line synchrony/release assay. *Biotech Histochem* 74(3):119-128.
40. Miljkovic D, Samardzic T, Drakulic D, Stosic-Grujicic S, & Trajkovic V (2002) Immunosuppressants leflunomide and mycophenolic acid inhibit fibroblast IL-6 production by distinct mechanisms. *Cytokine* 19(4):181-186.
41. Sakuma I, Stuehr DJ, Gross SS, Nathan C, & Levi R (1988) Identification of arginine as a precursor of endothelium-derived relaxing factor. *Proc Natl Acad Sci U S A* 85(22):8664-8667.
42. Meilhac O, Escargueil-Blanc I, Thiers JC, Salvayre R, & Negre-Salvayre A (1999) Bcl-2 alters the balance between apoptosis and necrosis, but does not prevent cell death induced by oxidized low density lipoproteins. *FASEB J* 13(3):485-494.
43. Timberlake WE & Griffin DH (1974) Differential effects of analogs of cycloheximide on protein and RNA synthesis in Achlya. *Biochim Biophys Acta* 349(1):39-46.
44. Yaginuma H, *et al.* (1996) A novel type of programmed neuronal death in the cervical spinal cord of the chick embryo. *J Neurosci* 16(11):3685-3703.
45. Goldberg IH & Rabinowitz M (1962) Actionmycin D inhibition of deoxyribonucleic acid-dependent synthesis of ribonucleic acid. *Science* 136:315-316.
46. Schwartz A, Matsui H, & Laughter AH (1968) Tritiated digoxin binding to (Na<sup>+</sup> + K<sup>+</sup>)-activated adenosine triphosphatase: possible allosteric site. *Science* 160(825):323-325.
47. Isaev NK, *et al.* (2000) Inhibition of Na(+),K(+)-ATPase activity in cultured rat cerebellar granule cells prevents the onset of apoptosis induced by low potassium. *Neurosci Lett* 283(1):41-44.
48. Sperandio S, *et al.* (2004) Paraptosis: mediation by MAP kinases and inhibition by AIP-1/Alix. *Cell Death Differ* 11(10):1066-1075.
49. Bennett BL, *et al.* (2001) SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. *Proc Natl Acad Sci U S A* 98(24):13681-13686.
50. Degterev A, *et al.* (2005) Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. *Nat Chem Biol* 1(2):112-119.
51. Handschumacher RE, Harding MW, Rice J, Drugge RJ, & Speicher DW (1984) Cyclophilin: a specific cytosolic binding protein for cyclosporin A. *Science* 226(4674):544-547.

52. Nakagawa T, *et al.* (2005) Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. *Nature* 434(7033):652-658.
53. Cho H, *et al.* (2004) Aurintricarboxylic acid translocates across the plasma membrane, inhibits protein tyrosine phosphatase and prevents apoptosis in PC12 cells. *Mol Cells* 18(1):46-52.
54. Batistatou A & Greene LA (1991) Aurintricarboxylic acid rescues PC12 cells and sympathetic neurons from cell death caused by nerve growth factor deprivation: correlation with suppression of endonuclease activity. *J Cell Biol* 115(2):461-471.
55. Lowe SW, Schmitt EM, Smith SW, Osborne BA, & Jacks T (1993) p53 is required for radiation-induced apoptosis in mouse thymocytes. *Nature* 362(6423):847-849.
56. Norbury CJ & Zhivotovsky B (2004) DNA damage-induced apoptosis. *Oncogene* 23(16):2797-2808.
57. Liang XH, *et al.* (1999) Induction of autophagy and inhibition of tumorigenesis by beclin 1. *Nature* 402(6762):672-676.
58. Adachi S, Cross AR, Babior BM, & Gottlieb RA (1997) Bcl-2 and the outer mitochondrial membrane in the inactivation of cytochrome c during Fas-mediated apoptosis. *J Biol Chem* 272(35):21878-21882.
59. Kroemer G, Galluzzi L, & Brenner C (2007) Mitochondrial membrane permeabilization in cell death. *Physiol Rev* 87(1):99-163.
60. Giodini A, *et al.* (2002) Regulation of microtubule stability and mitotic progression by survivin. *Cancer Res* 62(9):2462-2467.
61. Zaffaroni N, *et al.* (2002) Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. *Cell Mol Life Sci* 59(8):1406-1412.
62. Zaffaroni N, Pennati M, & Daidone MG (2005) Survivin as a target for new anticancer interventions. *J Cell Mol Med* 9(2):360-372.
63. Del Poeta M, *et al.* (1999) Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells. *Antimicrob Agents Chemother* 43(12):2862-2868.
64. Kano Y, *et al.* (1992) Effects of CPT-11 in combination with other anti-cancer agents in culture. *Int J Cancer* 50(4):604-610.
65. Pommier Y (2006) Topoisomerase I inhibitors: camptothecins and beyond. *Nat Rev Cancer* 6(10):789-802.
66. Andoh T, *et al.* (1987) Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. *Proc Natl Acad Sci U S A* 84(16):5565-5569.
67. Bjornsti MA, Benedetti P, Viglianti GA, & Wang JC (1989) Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. *Cancer Res* 49(22):6318-6323.
68. Eng WK, Fauchette L, Johnson RK, & Sternglanz R (1988) Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. *Mol Pharmacol* 34(6):755-760.

69. Hsiang YH & Liu LF (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. *Cancer Res* 48(7):1722-1726.
70. Liu LF, *et al.* (2000) Mechanism of action of camptothecin. *Ann N Y Acad Sci* 922:1-10.
71. Madden KR & Champoux JJ (1992) Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin. *Cancer Res* 52(3):525-532.
72. Cuvillier O, *et al.* (2001) Sphingosine generation, cytochrome c release, and activation of caspase-7 in doxorubicin-induced apoptosis of MCF7 breast adenocarcinoma cells. *Cell Death Differ* 8(2):162-171.
73. Gamen S, *et al.* (2000) Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes deltaprim loss, caspase-9 activity, and apoptosis in Jurkat cells. *Exp Cell Res* 258(1):223-235.
74. Bodley A, *et al.* (1989) DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. *Cancer Res* 49(21):5969-5978.
75. Allouche M, *et al.* (1997) Influence of Bcl-2 overexpression on the ceramide pathway in daunorubicin-induced apoptosis of leukemic cells. *Oncogene* 14(15):1837-1845.
76. Bhalla K, *et al.* (1993) High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. *Blood* 82(10):3133-3140.
77. Crespi MD, Ivanier SE, Genovese J, & Baldi A (1986) Mitoxantrone affects topoisomerase activities in human breast cancer cells. *Biochem Biophys Res Commun* 136(2):521-528.
78. Smith PJ, Morgan SA, Fox ME, & Watson JV (1990) Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells. *Biochem Pharmacol* 40(9):2069-2078.
79. Kamesaki S, *et al.* (1993) bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. *Cancer Res* 53(18):4251-4256.
80. Osheroff N (1989) Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. *Biochemistry* 28(15):6157-6160.
81. Yang L, Rowe TC, & Liu LF (1985) Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells. *Cancer Res* 45(11 Pt 2):5872-5876.
82. Prasad V, *et al.* (1998) Podophyllotoxin and nocodazole counter the effect of IKP104 on tubulin decay. *J Protein Chem* 17(7):663-668.
83. Tseng CJ, *et al.* (2002) Microtubule damaging agents induce apoptosis in HL 60 cells and G2/M cell cycle arrest in HT 29 cells. *Toxicology* 175(1-3):123-142.
84. Wilson L (1970) Properties of colchicine binding protein from chick embryo brain. Interactions with vinca alkaloids and podophyllotoxin. *Biochemistry* 9(25):4999-5007.

85. Brantley-Finley C, *et al.* (2003) The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide. *Biochem Pharmacol* 66(3):459-469.
86. Marantz R, Ventilla M, & Shelanski M (1969) Vinblastine-induced precipitation of microtubule protein. *Science* 165(892):498-499.
87. Lobert S, Vulevic B, & Correia JJ (1996) Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. *Biochemistry* 35(21):6806-6814.
88. Harmon BV, Takano YS, Winterford CM, & Potten CS (1992) Cell death induced by vincristine in the intestinal crypts of mice and in a human Burkitt's lymphoma cell line. *Cell Prolif* 25(6):523-536.
89. Owellen RJ, Owens AH, Jr., & Donigian DW (1972) The binding of vincristine, vinblastine and colchicine to tubulin. *Biochem Biophys Res Commun* 47(4):685-691.
90. Borisy GG & Taylor EW (1967) The mechanism of action of colchicine. Binding of colchicine-<sup>3</sup>H to cellular protein. *J Cell Biol* 34(2):525-533.
91. Borisy GG & Taylor EW (1967) The mechanism of action of colchicine. Colchicine binding to sea urchin eggs and the mitotic apparatus. *J Cell Biol* 34(2):535-548.
92. Haber JE, Peloquin JG, Halvorson HO, & Borisy GG (1972) Colcemid inhibition of cell growth and the characterization of a colcemid-binding activity in *Saccharomyces cerevisiae*. *J Cell Biol* 55(2):355-367.
93. Weisenberg RC, Borisy GG, & Taylor EW (1968) The colchicine-binding protein of mammalian brain and its relation to microtubules. *Biochemistry* 7(12):4466-4479.
94. Van Dyke MM & Dervan PB (1984) Echinomycin binding sites on DNA. *Science* 225(4667):1122-1127.
95. Waring MJ & Wakelin LP (1974) Echinomycin: a bifunctional intercalating antibiotic. *Nature* 252(5485):653-657.
96. Barrientos A & Moraes CT (1999) Titrating the effects of mitochondrial complex I impairment in the cell physiology. *J Biol Chem* 274(23):16188-16197.
97. Isenberg JS & Klaunig JE (2000) Role of the mitochondrial membrane permeability transition (MPT) in rotenone-induced apoptosis in liver cells. *Toxicol Sci* 53(2):340-351.
98. Li N, *et al.* (2003) Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. *J Biol Chem* 278(10):8516-8525.
99. Lindahl PE & Oberg KE (1960) Mechanism of the physiological action of rotenone. *Nature* 187:784.
100. Linsinger G, Wilhelm S, Wagner H, & Hacker G (1999) Uncouplers of oxidative phosphorylation can enhance a Fas death signal. *Mol Cell Biol* 19(5):3299-3311.
101. Loomis WF, Lipmann, F.J. (1948) Reversible inhibition of the coupling between phosphorylation and oxidation. *J Biol Chem* 173(2):807-808.
102. Hladky SB, Leung JC, & Fitzgerald WJ (1995) The mechanism of ion conduction by valinomycin: analysis of charge pulse responses. *Biophys J* 69(5):1758-1772.

103. Inai Y, *et al.* (1997) Valinomycin induces apoptosis of ascites hepatoma cells (AH-130) in relation to mitochondrial membrane potential. *Cell Struct Funct* 22(5):555-563.
104. Kleuser B, Rieter H, & Adam G (1985) Selective effects by valinomycin on cytotoxicity and cell cycle arrest of transformed versus nontransformed rodent fibroblasts in vitro. *Cancer Res* 45(7):3022-3028.
105. Dawson TL, Gores GJ, Nieminen AL, Herman B, & Lemasters JJ (1993) Mitochondria as a source of reactive oxygen species during reductive stress in rat hepatocytes. *Am J Physiol* 264(4 Pt 1):C961-967.
106. Keilin D, Hartree, E.F. (1939) Cytochrome Cytochrome Oxidase. *Proc Roy Soc London (Series B)* 127(847):167-191.
107. Wever R, Muijsers AO, van Gelder BF, Bakker EP, & van Buuren KJ (1973) Biochemical and biophysical studies on cytochrome c oxidase. XI. Reaction with azide. *Biochim Biophys Acta* 325(1):1-7.
108. Bertrand R, Solary E, O'Connor P, Kohn KW, & Pommier Y (1994) Induction of a common pathway of apoptosis by staurosporine. *Exp Cell Res* 211(2):314-321.
109. Matsumoto H & Sasaki Y (1989) Staurosporine, a protein kinase C inhibitor interferes with proliferation of arterial smooth muscle cells. *Biochem Biophys Res Commun* 158(1):105-109.
110. Tamaoki T, *et al.* (1986) Staurosporine, a potent inhibitor of phospholipid/Ca<sup>++</sup>-dependent protein kinase. *Biochem Biophys Res Commun* 135(2):397-402.
111. Yanagihara N, *et al.* (1991) Staurosporine: an effective inhibitor for Ca<sup>2+</sup>/calmodulin-dependent protein kinase II. *J Neurochem* 56(1):294-298.
112. Hidaka H, Inagaki M, Kawamoto S, & Sasaki Y (1984) Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. *Biochemistry* 23(21):5036-5041.
113. Jarvis WD, Turner AJ, Povirk LF, Traylor RS, & Grant S (1994) Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. *Cancer Res* 54(7):1707-1714.
114. Fisher JW & Roh BL (1964) Influence of Alkylating Agents on Kidney Erythropoietin Production. *Cancer Res* 24:983-988.
115. Muller C, Christodoulopoulos G, Salles B, & Panasci L (1998) DNA-Dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards. *Blood* 92(7):2213-2219.
116. Becker K & Schirmer RH (1995) 1,3-Bis(2-chloroethyl)-1-nitrosourea as thiol-carbamoylating agent in biological systems. *Methods Enzymol* 251:173-188.
117. Stahl W, Lenhardt S, Przybylski M, & Eisenbrand G (1992) Mechanism of glutathione-mediated DNA damage by the antineoplastic agent 1,3-bis(2-chloroethyl)-N-nitrosourea. *Chem Res Toxicol* 5(1):106-109.
118. Berman R & Steel GG (1984) Induced and inherent resistance to alkylating agents in human small-cell bronchial carcinoma xenografts. *Br J Cancer* 49(4):431-436.
119. Bono VH, Jr. (1976) Review of mechanism of action studies of the nitrosoureas. *Cancer Treat Rep* 60(6):699-702.

120. Dean SW, Johnson AB, & Tew KD (1986) A comparative analysis of drug-induced DNA effects in a nitrogen mustard resistant cell line expressing sensitivity to nitrosoureas. *Biochem Pharmacol* 35(7):1171-1176.
121. Hartley JA, Gibson NW, Kohn KW, & Mattes WB (1986) DNA sequence selectivity of guanine-N7 alkylation by three antitumor chloroethylating agents. *Cancer Res* 46(4 Pt 2):1943-1947.
122. Rock KL, *et al.* (1994) Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. *Cell* 78(5):761-771.
123. Shinohara K, *et al.* (1996) Apoptosis induction resulting from proteasome inhibition. *Biochem J* 317 ( Pt 2):385-388.
124. Myung J, Kim KB, & Crews CM (2001) The ubiquitin-proteasome pathway and proteasome inhibitors. *Med Res Rev* 21(4):245-273.
125. Adams J, *et al.* (1998) Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. *Bioorg Med Chem Lett* 8(4):333-338.
126. Teicher BA, Ara G, Herbst R, Palombella VJ, & Adams J (1999) The proteasome inhibitor PS-341 in cancer therapy. *Clin Cancer Res* 5(9):2638-2645.
127. Medina V, *et al.* (1997) Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. *Cancer Res* 57(17):3697-3707.
128. Yoshida M, Horinouchi S, & Beppu T (1995) Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. *Bioessays* 17(5):423-430.
129. Yoshida M, Kijima M, Akita M, & Beppu T (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. *J Biol Chem* 265(28):17174-17179.
130. Beckers T, *et al.* (2007) Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. *Int J Cancer* 121(5):1138-1148.
131. Saito A, *et al.* (1999) A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. *Proc Natl Acad Sci U S A* 96(8):4592-4597.
132. Su GH, Sohn TA, Ryu B, & Kern SE (2000) A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. *Cancer Res* 60(12):3137-3142.
133. Takai N, Ueda T, Nishida M, Nasu K, & Narahara H (2006) A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells. *Int J Mol Med* 17(2):323-329.